# 2025年12月20日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 整合多组学与药物敏感性分析揭示儿科实体瘤的潜在生物标志物与治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417259)
**期刊：** Cancer research
**PMID：** 41417259
**DOI：** 10.1158/0008-5472.CAN-24-1938

### 第一部分 原文与翻译

**英文原标题：** Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors.

> **英文摘要：**
> UNLABELLED: Cure rates for childhood malignancies using established therapy protocols have increased to an average of 80% but have reached a plateau. Moreover, survival rates are particularly low for some pediatric tumors-such as high-risk group 3 medulloblastomas, osteosarcomas, Ewing sarcomas, high-risk neuroblastomas, and high-grade gliomas-and dismal for patients with relapsed malignancies. A functional drug response profiling platform for pediatric solid and brain tumors has been established within the INFORM program to identify patient-specific vulnerabilities and biomarkers and to unravel molecular mechanisms associated with drug response profiles for clinical translation. In this study, we performed a multiomics analysis using drug sensitivity profiles, as well as genomic and transcriptomic data, of 81 pediatric solid tumor samples. The integrative analysis suggested two multiomics signatures associated with drug sensitivity. One signature distinguished neuroblastoma samples with sensitivity to navitoclax, a BCL2 family inhibitor. A second signature was specific to a subset of Wilms tumors harboring the SIX1 (Q177R) hotspot mutation that displayed high expression of MGAM, PTPN14, STAT4, and KDM2B and high sensitivity to MEK inhibitors. A patient-specific causal interaction network analysis suggested possible molecular interactions between MEK inhibitors and the SIX1 mutation in Wilms tumor samples. In conclusion, the integration of drug sensitivity profiling and multiomics data revealed potential biomarkers that may be associated with drug sensitivity in pediatric solid tumors. Patient-specific causal interaction network analysis further elucidated the interaction between inhibitors and signature biomarkers, providing insights that may inform clinical translation.
> 
> SIGNIFICANCE: The combination of multiomics analysis and drug sensitivity profiling identified two signatures related to drug sensitivity in pediatric solid tumors, contributing to the advancement of functional precision medicine and personalized treatment strategies. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .

> **中文摘要：**
> 【未加标注】：通过应用既定治疗方案，小儿恶性肿瘤的治愈率已提高至平均80%，但目前已趋于平台期。此外，某些小儿肿瘤的生存率仍然特别低，例如高危3型髓母细胞瘤、骨肉瘤、尤文肉瘤、高危神经母细胞瘤以及高级别神经胶质瘤；复发性恶性肿瘤患者的预后尤其不理想。在INFORM项目中，为儿童实体瘤和脑肿瘤建立了一个功能性药物反应谱分析平台，以识别患者特异性的脆弱性和生物标志物，并揭示与药物反应特征相关的分子机制，以促进临床转化。在本研究中，我们对81例儿科实体瘤样本开展了整合性的多组学分析，结合其药物敏感性谱、基因组及转录组数据。整合分析提示存在两种与药物敏感性相关的多组学特征。一种特征可区分对navitoclax（一种BCL2家族抑制剂）敏感的神经母细胞瘤样本。另一种特征特异性出现在携带SIX1 (Q177R)热点突变的部分Wilms瘤中，该特征表现为MGAM、PTPN14、STAT4及KDM2B的高表达，并对MEK抑制剂表现出高度敏感性。患者特异性的因果交互网络分析提示，在Wilms瘤样本中，MEK抑制剂与SIX1突变之间可能存在分子相互作用。综上所述，药物敏感性谱与多组学数据的整合揭示了可能与药物敏感性相关的潜在生物标志物。患者特异性因果交互网络分析进一步阐明了抑制剂与特征性生物标志物之间的相互作用，为临床转化提供了新的见解。
> 
> 【意义】：多组学分析与药物敏感性分析的结合确定了两种与儿科实体瘤药物敏感性相关的特征，有助于推动功能性精准医学与个体化治疗策略的发展。本文属于专题系列之一：“以计算研究、数据科学与机器学习/人工智能推动癌症发现”。

### 第二部分 AI 大师评价

该研究旨在通过整合多组学数据与药物敏感性谱，揭示影响儿科实体瘤药物反应的关键生物标志物与潜在治疗途径。研究团队利用INFORM项目收集的81例样本进行整合分析，识别出两种与药物敏感性相关的分子特征，分别与BCL2家族抑制剂及MEK抑制剂的反应相关。其创新之处在于结合因果交互网络分析，从机制层面探索基因突变与药物反应之间的分子联系。该方法为功能精准医学提供了重要的数据支持，但样本量有限，仍需进一步验证其临床可行性与预测价值。

---

## 2. 一种共价变构分子胶抑制NRF2依赖的肿瘤生长

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41417010)
**期刊：** Cancer discovery
**PMID：** 41417010
**DOI：** 10.1158/2159-8290.CD-25-1187

### 第一部分 原文与翻译

**英文原标题：** A covalent allosteric molecular glue suppresses NRF2-dependent cancer growth.

> **英文摘要：**
> The NRF2 transcription factor is constitutively active in cancer where it functions to maintain oxidative homeostasis and reprogram cellular metabolism. NRF2-active tumors exhibit NRF2-dependency and resistance to chemo/radiotherapy. Here we characterize VVD-065, a first-in-class NRF2 inhibitor that acts via an unprecedented allosteric molecular glue mechanism. In the absence of stress or mutation, NRF2 is rapidly degraded by the KEAP1-CUL3 ubiquitin-ligase complex. VVD-065 specifically and covalently engages Cys151 on KEAP1, which in turn promotes KEAP1-CUL3 complex formation, leading to enhancement of NRF2 degradation. Previously reported Cys151-directed compounds decrease KEAP1-CUL3 interactions and stabilize NRF2, thus establishing KEAP1_Cys151 as a tunable regulator of the KEAP1-CUL3 complex and NRF2 stability. VVD-065 inhibited NRF2-dependent tumor growth and sensitized cancers to chemo/radiotherapy, supporting an open Phase I clinical trial (NCT05954312).

> **中文摘要：**
> NRF2转录因子在癌症中持续活跃，其功能是维持氧化还原稳态并重编程细胞代谢。NRF2活性的肿瘤表现出对NRF2的依赖性以及对化疗/放疗的耐受性。本研究表征了VVD-065，这是一种首创的NRF2抑制剂，其通过一种前所未有的变构分子胶机制发挥作用。在无应激或突变的情况下，NRF2会被KEAP1-CUL3泛素连接酶复合物迅速降解。VVD-065可特异性且共价地结合于KEAP1上的Cys151，从而促进KEAP1-CUL3复合物的形成，增强NRF2的降解。此前报道的靶向Cys151的化合物会降低KEAP1-CUL3相互作用并稳定NRF2，因此确立了KEAP1_Cys151作为KEAP1-CUL3复合物和NRF2稳定性的可调节调控位点。VVD-065抑制了NRF2依赖的肿瘤生长，并增加了肿瘤对化疗/放疗的敏感性，从而支持其进入开放的I期临床试验（NCT05954312）。

### 第二部分 AI 大师评价

该研究旨在开发并阐释一种新型NRF2抑制剂VVD-065的作用机制，揭示其通过共价结合KEAP1的关键残基Cys151并促进KEAP1-CUL3复合物形成，从而加速NRF2降解的独特变构分子胶机制。结果显示，VVD-065能够有效抑制NRF2依赖的肿瘤生长并增强肿瘤对化疗/放疗的敏感性。研究创新性地重新定义了KEAP1_Cys151在复合物组装与NRF2调控中的可塑角色，为抗NRF2驱动肿瘤提供了全新策略。但其临床安全性与长期疗效仍需进一步验证。

---

## 3. 血清素通过表观遗传重编程调控神经内分泌型前列腺癌的谱系可塑性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41416996)
**期刊：** Cancer discovery
**PMID：** 41416996
**DOI：** 10.1158/2159-8290.CD-25-0974

### 第一部分 原文与翻译

**英文原标题：** Serotonin modulates lineage plasticity in neuroendocrine prostate cancer via epigenetic reprogramming.

> **英文摘要：**
> Neuroendocrine prostate cancer (NEPC) is an aggressive, therapy-resistant subtype of prostate cancer characterized by lineage plasticity. While metabolic and signaling molecules are increasingly recognized as modulators of tumor progression, their role in cell fate transition remains unclear. NE tumors produce and accumulate serotonin, a neurotransmitter that regulates diverse physiological processes. Here, we identify a tumor-intrinsic serotonin axis as key driver of NEPC lineage commitment and progression. NEPC endogenously synthesize serotonin via aromatic L-amino acid decarboxylase (DDC) and reuptake through the transporter SLC6A4. Mechanistically, high level of intracellular serotonin promotes histone serotonylation at H3K4me3Q5, reconfiguring the H3K4me3 chromatin landscape and downstream gene expression, which drives induced NE differentiation and is associated with suppressed androgen receptor signaling. Pharmacological inhibition of 5-HT synthesis using the FDA-approved DDC inhibitor carbidopa significantly impairs tumor growth and prolongs survival in both genetically engineered and patient-derived xenograft models, highlighting histone serotonylation as a druggable vulnerability in NEPC.

> **中文摘要：**
> 神经内分泌型前列腺癌（NEPC）是一种具有谱系可塑性、侵袭性强且对治疗具有耐受性的前列腺癌亚型。尽管代谢和信号分子越来越被认为是肿瘤进展的调节因子，但它们在细胞命运转变中的作用仍不清楚。神经内分泌肿瘤会产生并积累血清素，这是一种调控多种生理过程的神经递质。在本研究中，我们鉴定出一种肿瘤内源性的血清素轴，作为驱动NEPC谱系承诺和进展的关键因素。NEPC通过芳香族L-氨基酸脱羧酶（DDC）内源性合成血清素，并通过转运蛋白SLC6A4实现再摄取。从机制上看，高水平的细胞内血清素可促进组蛋白H3K4me3Q5位点的血清素化，重新配置H3K4me3染色质景观及其下游基因表达，从而驱动诱导性神经内分泌分化，并伴随雄激素受体信号的抑制。使用美国FDA批准的DDC抑制剂卡比多巴药理性抑制5-HT合成可显著抑制肿瘤生长，并延长基因工程小鼠及患者来源异种移植模型的生存期，这突显组蛋白血清素化是NEPC中可被药物靶向的脆弱点。

### 第二部分 AI 大师评价

本研究揭示了血清素在神经内分泌型前列腺癌谱系转化中的关键作用，阐明其通过组蛋白血清素化介导的表观遗传重编程机制。作者利用分子机制研究结合动物模型验证，证明抑制血清素合成能够延缓肿瘤进展并提高生存期。该发现不仅深化了对肿瘤谱系可塑性的理解，也提出了组蛋白血清素化作为潜在治疗靶点的新思路。其创新性在于将神经递质信号与表观遗传调控相结合，但未来仍需在临床可行性及耐药性方面进一步探索。

---

## 4. 以生物学为导向的晚期胆道癌纳米白蛋白紫杉醇联合吉西他滨-顺铂治疗分层：一项前瞻性观察性队列研究。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41416898)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41416898
**DOI：** 10.1097/HEP.0000000000001650

### 第一部分 原文与翻译

**英文原标题：** Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine-cisplatin: A prospective observational cohort study.

> **英文摘要：**
> BACKGROUND AIMS: Nab-paclitaxel plus gemcitabine-cisplatin (Gem/Cis/nab-P) had promising efficacy in phase II trials for advanced biliary tract cancer (BTC) but failed to demonstrate superiority in phase III. We investigated Gem/Cis/nab-P efficacy and identified molecular subgroups with clinical benefit.
> 
> APPROACH RESULTS: This prospective observational cohort study (NCT04871321) enrolled 119 patients with advanced BTC who received Gem/Cis/nab-P from July 2021 to December 2022. Of these, 108 were included in genomic and transcriptomic analyses of pretreatment tumor samples that met quality control criteria. Among 119 patients, 39.5% had intrahepatic cholangiocarcinoma, 37.0% extrahepatic cholangiocarcinoma, and 23.5% gallbladder cancer. Most patients had metastatic disease (68.9%). At a median follow-up of 23.7 months, the median progression-free survival was 8.3 months and median overall survival 19.8 months. Grade ≥3 treatment-related adverse events occurred in 70 patients (58.8%), and dose reduction was required in 99.2%. Frequent genetic alterations were TP53 (53.7%), KRAS (29.6%), and CDKN2A (20.4%), with TP53 mutations being significantly associated with worse outcomes. Transcriptomic analysis identified four molecular subtypes: cholangiocyte-like, stromal, metabolic, and inflammatory-proliferative. The cholangiocyte-like subtype, marked by increased cholangiocyte markers, had the most favorable prognosis. Stromal and metabolic subtypes showed moderate outcomes, characterized by a fibroblast-rich stroma with activated angiogenesis and enriched metabolic pathways, respectively. The inflammatory-proliferative subtype had the worst prognosis, with cell cycle and inflammatory activation, and an exhausted immune microenvironment.
> 
> CONCLUSIONS: This study demonstrated the clinical activity of Gem/Cis/nab-P in advanced BTC and highlighted that biology-driven patient stratification based on genomic and transcriptomic features may provide important prognostic information.

> **中文摘要：**
> 研究背景与目的：纳米白蛋白紫杉醇联合吉西他滨-顺铂（Gem/Cis/nab-P）在晚期胆道癌（BTC）II期临床试验中显示了良好疗效，但在III期中未能证明其优越性。本研究评估了Gem/Cis/nab-P的疗效，并识别出可能获益的分子亚群。
> 
> 研究方法与结果：这项前瞻性观察性队列研究（NCT04871321）共纳入119例接受Gem/Cis/nab-P治疗的晚期BTC患者，入组时间为2021年7月至2022年12月。其中108例满足质量控制标准的治疗前肿瘤样本接受了基因组和转录组分析。在119例患者中，39.5%为肝内胆管癌，37.0%为肝外胆管癌，23.5%为胆囊癌。多数患者存在转移性疾病（68.9%）。在中位随访23.7个月后，中位无进展生存期为8.3个月，中位总生存期为19.8个月。共有70例（58.8%）出现≥3级治疗相关不良事件，99.2%的患者需要减量治疗。常见基因变异包括TP53（53.7%）、KRAS（29.6%）和CDKN2A（20.4%），其中TP53突变与较差预后显著相关。转录组分析鉴定出四种分子亚型：胆管细胞样型、间质型、代谢型和炎症-增殖型。胆管细胞样亚型表现为胆管细胞标志物上调，预后最佳；间质型和代谢型预后中等，前者特征为富含成纤维细胞基质及血管生成活化，后者富集代谢通路；炎症-增殖型预后最差，表现为细胞周期与炎症活化以及免疫微环境耗竭。
> 
> 研究结论：本研究验证了Gem/Cis/nab-P在晚期BTC中的临床活性，并强调基于基因组与转录组特征的生物学分层可为患者预后提供重要信息。

### 第二部分 AI 大师评价

该研究旨在评估纳米白蛋白紫杉醇联合吉西他滨-顺铂在晚期胆道癌中的真实世界疗效，并探讨其分子分型特征与临床获益的关联。研究通过对119例患者的前瞻性观察与多组学分析，揭示了不同生物亚型的预后差异。尤其是胆管细胞样亚型显示出较优生存，而TP53突变和炎症-增殖型则提示不良结局。该工作创新性地提出了“生物学驱动分层”理念，但受样本量和观察性设计限制，仍需进一步验证。

---

## 5. 关于“CellMiner 跨数据库（CellMinerCDB）版本 2.2：用于探索患者来源癌细胞系药物基因组学”的更正声明。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41416409)
**期刊：** Nucleic acids research
**PMID：** 41416409
**DOI：** 10.1093/nar/gkaf1468

### 第一部分 原文与翻译

**英文原标题：** Correction to 'CellMiner cross-database (CellMinerCDB) version 2.2 for explorations of patient-derived cancer cell line pharmacogenomics'.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本文为《Nucleic Acids Research》期刊中关于 CellMinerCDB 2.2 版的更正通知。该内容说明了作者对先前发表文章的修订或信息更新，属于学术维护性质的出版内容。此类更正通常涉及数据、软件版本或解释性内容的微调，对保证数据库工具的准确性和可重复性具有重要意义。尽管无新研究数据，但其体现了研究团队对科研透明性与持续改进的重视。

---

## 6. 采用质子放射治疗颅底及颈椎软骨肉瘤的前瞻性随机剂量递增试验：PROG 85-26 项目的30年随访结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41414803)
**期刊：** Neuro-oncology
**PMID：** 41414803
**DOI：** 10.1093/neuonc/noaf289

### 第一部分 原文与翻译

**英文原标题：** Prospective, Randomized Dose Escalation Trial with Proton-Based Radiation for Skull Base and Cervical Spine Chondrosarcomas: 30-year outcomes from PROG 85-26.

> **英文摘要：**
> BACKGROUND: To determine if dose escalation improves outcomes for chondrosarcomas (CHS) of the base of the skull (BOS) and the cervical spine (CS).
> 
> METHODS: A prospective, randomized, dose-escalation trial was designed for patients with CHS of the BOS and CS. Patients were randomly assigned to 70 Gy (RBE) or 76 Gy (RBE). The primary endpoint was local failure (LF). Secondary endpoints included overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), and treatment-related toxicities.
> 
> RESULTS: Between 1987 and 2007, 105 patients were randomized, median follow-up was 29.2 years (IQR, 26.7-32.4). Forty-six patients were assigned to 70 Gy (RBE) and fifty-nine were assigned to 76 Gy (RBE). LF at 5-, 10-, and 20 years were 7%, 9%, and 11% for 70 Gy (RBE), and 10%, 15%, and 19% for 76 Gy (RBE) (p = 0.16). Like LF rates, there was no benefit in dose escalation for OS (p = 0.28) and CSS (p = 0.22). Progression-free survival at 5-, 10-, and 20 years was 93%, 89%, and 77% for the low-dose group and 83%, 71%, and 59% for the high-dose group (p = 0.069). Late RT injury ≥ grade 3 was reported in a total of 19 (18%) patients across both dose levels, with 11% in the low-dose group and 24% in the high-dose group (p = 0.13).
> 
> CONCLUSIONS: This is the first and largest trial of patients with grade I/II BOS and CS CHS evaluating dose escalation for tumor control. Proton-based RT is effective and safe for these tumors, but there is no apparent benefit in dose escalation.

> **中文摘要：**
> 背景：旨在确定剂量递增是否能改善颅底（BOS）及颈椎（CS）软骨肉瘤（CHS）的治疗结局。
> 
> 方法：设计了一项前瞻性、随机化的剂量递增试验，纳入BOS及CS部位CHS患者。患者被随机分配接受70 Gy（RBE）或76 Gy（RBE）照射。主要终点为局部失败（LF）；次要终点包括总体生存（OS）、癌症特异性生存（CSS）、无进展生存（PFS）及治疗相关毒性。
> 
> 结果：1987年至2007年间，共105例患者被随机分组，中位随访时间为29.2年（四分位距26.7-32.4）。其中46例接受70 Gy（RBE），59例接受76 Gy（RBE）。在5年、10年及20年时，70 Gy（RBE）组的LF率分别为7%、9%和11%，而76 Gy（RBE）组分别为10%、15%和19%（p=0.16）。与LF类似，剂量递增在OS（p=0.28）和CSS（p=0.22）方面亦未显示优势。低剂量组在5年、10年和20年的PFS分别为93%、89%和77%，而高剂量组分别为83%、71%和59%（p=0.069）。两组共有19例（18%）患者出现≥3级的放疗晚期损伤，其中低剂量组为11%，高剂量组为24%（p=0.13）。
> 
> 结论：本研究为首个也是规模最大的关于BOS及CS部位I/II级CHS患者的剂量递增试验。结果表明，基于质子的放射治疗对这些肿瘤安全且有效，但剂量递增并未带来明显获益。

### 第二部分 AI 大师评价

本研究是一项历时30年的前瞻性、随机剂量递增试验，评估质子放疗在颅底及颈椎软骨肉瘤中的疗效。结果显示，尽管高剂量组未在局部控制、总体生存和特异性生存方面获得显著优势，却呈现出较高的放射损伤风险。该研究是该领域规模最大、随访时间最长的剂量递增临床试验，强化了质子放疗的长期安全有效性。但其局限在于未能证明剂量递增的额外价值，提示现行剂量可能已达最佳平衡点。

---

## 7. ACSS2介导的乙酰辅酶A积累通过增加H3K27ac促进HBV相关肝细胞癌的线粒体自噬与肿瘤生长

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41414763)
**期刊：** Clinical and molecular hepatology
**PMID：** 41414763
**DOI：** 10.3350/cmh.2025.0754

### 第一部分 原文与翻译

**英文原标题：** ACSS2-mediated acetyl-CoA accumulation promotes mitophagy and tumor growth via increased H3K27ac in HBV-related HCC.

> **英文摘要：**
> BACKGROUND/AIMS: Acetyl coenzyme A (acetyl-CoA) is one of the most essential metabolites in cell metabolism but its function and concentration in hepatocellular carcinoma (HCC) remains elusive and controversial.
> 
> METHODS: A comprehensive analysis of acetyl-CoA levels and ACSS2 expression across a range of samples, including patient specimens from both HBV positive and HBV negative HCC individuals, HBV-transgenic mouse HCC models, and multiple cell lines. Furthermore, to evaluate the functional significance of ACSS2 in HBV-related HCC, we implemented both genetic and pharmacological inhibition strategies targeting ACSS2. Molecular mechanism and mitophagy assessment were revealed by CUT &Tag, RNA sequencing, bioinformatic analyses, transmission electron microscopy (TEM) and JC-1 staining.
> 
> RESULTS: Our study revealed a distinct metabolic signature of HBV-related HCC, marked by elevated acetyl-CoA, which was driven by acetyl-CoA synthetase 2 (ACSS2). ACSS2 was upregulated by the carbohydrate response element-binding protein (ChREBP) in HBV-related HCC. Furthermore, ACSS2 improved tumor cell proliferation, an effect that was dependent on its enzymatic activity. Mechanistically, ACSS2-induced acetyl-CoA accumulation activated voltage-dependent anion channels 1 (VDAC1) transcription through increased H3K27ac occupancy, which subsequently promoted mitophagy and HBV-related HCC tumorigenesis. Notably, targeting ACSS2 by depletion or inhibition with a catalytic inhibitor significantly suppressed tumor growth.
> 
> CONCLUSIONS: These findings not only illustrate the interplay between metabolic reprogramming, epigenetic modification, and tumorigenesis in the context of HBV infection, but also highlight ACSS2 as a novel metabolic vulnerability in HBV-related HCC. Therefore, targeting ACSS2 could be a novel strategy against HBV-associated HCC.

> **中文摘要：**
> 背景/目的：乙酰辅酶A（acetyl-CoA）是细胞代谢中最重要的代谢物之一，但其在肝细胞癌（HCC）中的功能和浓度仍不清楚且存在争议。
> 
> 方法：本研究对多种样本中乙酰辅酶A水平及ACSS2表达进行了综合分析，这些样本包括HBV阳性和HBV阴性的HCC患者组织、HBV转基因小鼠HCC模型以及多种细胞系。此外，为评估ACSS2在HBV相关HCC中的功能意义，我们采用了针对ACSS2的遗传学和药理学抑制策略。分子机制及线粒体自噬评估通过CUT & Tag、RNA测序、生物信息学分析、透射电子显微镜（TEM）及JC-1染色进行揭示。
> 
> 结果：我们的研究发现HBV相关HCC具有独特的代谢特征，其特征为乙酰辅酶A水平升高，而这一变化由乙酰辅酶A合成酶2（ACSS2）驱动。在HBV相关HCC中，ACSS2受碳水化合物反应元件结合蛋白（ChREBP）上调。此外，ACSS2可促进肿瘤细胞增殖，此作用依赖于其酶活性。从机制上看，ACSS2诱导的乙酰辅酶A积累通过增加H3K27ac的富集激活了电压依赖性阴离子通道1（VDAC1）的转录，从而促进线粒体自噬和HBV相关HCC的肿瘤发生。值得注意的是，通过耗竭或使用催化性抑制剂抑制ACSS2可显著抑制肿瘤生长。
> 
> 结论：这些研究结果不仅揭示了HBV感染背景下代谢重编程、表观遗传修饰和肿瘤发生之间的相互作用，还突出了ACSS2作为HBV相关HCC的新型代谢脆弱性。因此，以ACSS2为靶点可能成为针对HBV相关HCC的创新治疗策略。

### 第二部分 AI 大师评价

本研究针对HBV相关肝细胞癌的代谢机制展开，系统分析了ACSS2介导的乙酰辅酶A积累在肿瘤进展中的作用。作者通过多种模型与组学手段发现，ACSS2通过上调H3K27ac促进VDAC1转录，从而增强线粒体自噬并推动肿瘤生长。研究揭示了代谢重编程与表观遗传调控之间的耦合关系，提出ACSS2是HBV相关HCC的重要代谢脆弱点。尽管仍需进一步验证临床可行性，但该工作为代谢靶向治疗提供了新的方向。

---

## 8. 多西他赛诱导的GSDME通路激活及细胞焦亡增强前列腺癌细胞的免疫致死效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413917)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41413917
**DOI：** 10.1186/s13046-025-03614-1

### 第一部分 原文与翻译

**英文原标题：** Docetaxel induced activation of GSDME pathway and pyroptosis enhance immune lethality in prostate cancer cells.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

本研究探讨了化疗药物多西他赛通过激活GSDME通路引发细胞焦亡，从而增强免疫系统对前列腺癌细胞杀伤作用的机制。该工作揭示了传统化疗药物可能通过免疫相关细胞死亡途径发挥抗肿瘤效应，拓展了多西他赛的作用机制。虽然目前缺乏详细摘要，但该题目暗示研究具有较高的转化潜力，为抗癌化疗与免疫治疗的联合策略提供了新思路。

---

## 9. 在接受微创食管切除术或机器人辅助微创食管切除术患者中行幽门成形术与否的Ⅲ期随机对照试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413794)
**期刊：** Annals of surgery
**PMID：** 41413794
**DOI：** 10.1097/SLA.0000000000006997

### 第一部分 原文与翻译

**英文原标题：** A Phase III Randomized Controlled Trial of Pyloroplasty versus No Pyloroplasty in Patients Undergoing Minimally Invasive Esophagectomy or Robot-Assisted Minimally Invasive Esophagectomy.

> **英文摘要：**
> OBJECTIVE: To assess the value of adding of a pyloroplasty procedure during the performance of minimally invasive esophagectomy (MIE) or robotically assisted MIE (RAMIE), we conducted a prospective, phase III randomized controlled trial (RCT)(NCT03740542).
> 
> BACKGROUND: Many surgeons include pyloroplasty when performing esophagectomy, but few studies have provided level 1 evidence to support or refute this step especially in the era of MIE and RAMIE.
> 
> METHODS: An adaptive randomization trial design was utilized to maximize patients treated on more effective therapy and conversely minimize accrual to a less effective procedure. The trial was designed to proceed until one arm was established as superior or until a total of 140 patients had been treated and deemed evaluable for response. The primary endpoints of the study were pneumonia and/or anastomotic leak requiring surgery within 30 days of surgery.
> 
> RESULTS: Over a 4-year period, 143 patients were randomized, and 134 patients were evaluable. The greater likelihood of success for pyloroplasty throughout the trial resulted in more patients randomized towards pyloroplasty (n= 90) vs. no pyloroplasty (n=44). Pneumonia or an anastomotic leak occurred in 16 of 90 (18%) patients in the pyloroplasty arm vs. 12 of 44 (27%) in the no-pyloroplasty arm. The stopping criteria were met when the posterior probability of pyloroplasty being superior reached 90%.
> 
> CONCLUSIONS: The design of this trial led to early stopping because the short-term results indicated that outcomes in the pyloroplasty arm were superior to the no-pyloroplasty arm. This RCT provides evidence for short-term benefits of adding pyloroplasty to MIE or RAMIE. The long-term outcomes and quality of life measures continue to be monitored.

> **中文摘要：**
> 目的：为评估在实施微创食管切除术（MIE）或机器人辅助微创食管切除术（RAMIE）过程中增加幽门成形术的价值，我们开展了一项前瞻性Ⅲ期随机对照试验（RCT）（NCT03740542）。
> 
> 背景：许多外科医生在进行食管切除术时会合并幽门成形术，但很少有研究提供一级证据以支持或反对这一操作，尤其是在MIE和RAMIE时代。
> 
> 方法：本研究采用自适应随机化试验设计，以最大限度地使患者接受更有效的治疗，同时尽量减少分配到较低效手术方式的患者。试验设计为直至某一组被确立为优越者，或共计140例患者完成治疗并具备反应评估为止。主要终点为术后30天内发生的肺炎和/或需外科干预的吻合口漏。
> 
> 结果：在4年的研究期间，共随机入组143例患者，其中134例可评估。由于在试验过程中幽门成形术显示出更高的成功概率，因此更多患者被随机分配至幽门成形术组（n=90）而非非幽门成形组（n=44）。肺炎或吻合口漏的发生率在幽门成形组为16/90（18%），在非幽门成形组为12/44（27%）。当幽门成形术优越性的后验概率达到90%时，满足了试验的终止标准。
> 
> 结论：由于短期结果显示幽门成形术组的预后优于非幽门成形组，本试验提前终止。本RCT为在MIE或RAMIE中增加幽门成形术的短期获益提供了证据。长期结局及生活质量指标仍在持续监测中。

### 第二部分 AI 大师评价

该研究通过Ⅲ期自适应随机对照试验，评估在微创或机器人辅助食管切除术中是否应常规实施幽门成形术。结果显示，幽门成形术可降低术后肺炎或吻合口漏的发生率，短期预后优于不实施该术式者。该试验设计合理并因疗效差异显著而提前终止，具有较强的临床指导意义。其创新性在于提供了MIE/RAMIE背景下一级证据，但长期随访和生活质量影响仍需进一步验证。

---

## 10. IRF2BPL通过转录性调控IGFBP2促进食管鳞状细胞癌的肿瘤进展并抑制免疫细胞浸润

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413713)
**期刊：** Oncogene
**PMID：** 41413713
**DOI：** 10.1038/s41388-025-03658-9

### 第一部分 原文与翻译

**英文原标题：** IRF2BPL transcriptionally regulates IGFBP2 to promote tumor progression and suppresses immune cell infiltration in esophageal squamous cell carcinoma.

> **英文摘要：**
> Numerous ubiquitination-related proteases (URPs) have been identified as facilitators of disease progression through the disruption of ubiquitination homeostasis in substrate proteins. Notably, some URPs have exhibited non-classical biological functions. In this study, we experimentally elucidate the role of the E3 ubiquitin ligase IRF2BPL as transcriptional activator that promotes malignant phenotypes in esophageal squamous cell carcinoma (ESCC) and inhibits the infiltration of various immune cells within the tumor microenvironment. Specifically, we found that IRF2BPL is highly expressed in ESCC cells and promotes IGFBP2 transcription, thereby facilitating ESCC development both in vivo and in vitro. Moreover, the chemical drug ONC201 was shown to effectively impede ESCC progression induced by the hyperactive IRF2BPL-IGFBP2 axis in tumor cells. Collectively, our findings verified that the IRF2BPL-IGFBP2 axis plays a critical role in enhancing ESCC progression by increasing the malignancy of ESCC cells and fostering an immune-deficient tumor microenvironment. Targeting the IRF2BPL-IGFBP2 axis may represent a promising therapeutic strategy for ESCC.

> **中文摘要：**
> 众多泛素化相关蛋白酶（URPs）已被鉴定为通过破坏底物蛋白的泛素化稳态而促进疾病进展的因素。值得注意的是，一些URPs表现出非经典的生物学功能。在本研究中，我们通过实验阐明了E3泛素连接酶IRF2BPL作为一种转录性激活因子的作用，该因子能够促进食管鳞状细胞癌（ESCC）的恶性表型，并抑制肿瘤微环境中多种免疫细胞的浸润。具体而言，我们发现IRF2BPL在ESCC细胞中高表达，并促进IGFBP2的转录，从而在体内和体外均促进ESCC的发展。此外，化学药物ONC201被证明能够有效阻断由高活性的IRF2BPL-IGFBP2轴诱导的ESCC进展。总体而言，我们的研究结果验证了IRF2BPL-IGFBP2轴在增强ESCC进展中的关键作用，其机制包括提高ESCC细胞的恶性程度并诱导免疫缺陷型肿瘤微环境。靶向IRF2BPL-IGFBP2轴可能代表一种有前景的ESCC治疗策略。

### 第二部分 AI 大师评价

本研究揭示了E3泛素连接酶IRF2BPL在食管鳞癌中的异常高表达及其通过转录激活IGFBP2促进肿瘤进展的分子机制。研究采用体内外实验验证了IRF2BPL-IGFBP2轴在调控肿瘤恶性行为和抑制免疫细胞浸润中的作用，并发现小分子药物ONC201能够有效干预该通路。该研究创新性地揭示了IRF2BPL的转录激活功能及其在免疫逃逸中的潜在作用，为ESCC治疗提供了新的靶点思路。局限性可能在于临床验证及免疫调控机制尚需进一步深入研究。

---

## 11. 出版者更正：共价靶向放射性配体增强放射核素治疗效力。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413652)
**期刊：** Nature
**PMID：** 41413652
**DOI：** 10.1038/s41586-025-09982-0

### 第一部分 原文与翻译

**英文原标题：** Publisher Correction: Covalent targeted radioligands potentiate radionuclide therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该条目属于出版者更正，涉及关于共价靶向放射性配体增强放射核素治疗的原始研究。此类更正通常关注文献中的排版、数据或图表错误，而不影响研究的主要科学结论。该研究主题体现了靶向放射性药物的发展前沿，具有在精准放射治疗中提高疗效的潜力。更正的发布体现了期刊对学术严谨性与数据准确性的高度重视。

---

## 12. 靶向TRIM59可损害RNA剪接并促进神经母细胞瘤分化及治疗反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413601)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41413601
**DOI：** 10.1186/s13046-025-03573-7

### 第一部分 原文与翻译

**英文原标题：** Targeting TRIM59 impairs RNA splicing and promotes neuroblastoma differentiation and therapeutic responses.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于TRIM59在神经母细胞瘤发生与治疗中的作用，揭示其可能通过影响RNA剪接过程调控肿瘤细胞分化与治疗敏感性。该研究提示TRIM59不仅是神经母细胞瘤潜在的分子标志物，也可能成为新的治疗靶点。尽管摘要缺失，但从题目可推测研究具有较强的机制探索与转化医学意义，未来有望推动神经母细胞瘤精准治疗策略的发展。

---

## 13. 肿瘤微环境中的癌相关成纤维细胞：异质性、交互机制及治疗学意义

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413569)
**期刊：** Molecular cancer
**PMID：** 41413569
**DOI：** 10.1186/s12943-025-02533-1

### 第一部分 原文与翻译

**英文原标题：** Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications.

> **英文摘要：**
> The tumor microenvironment (TME) is increasingly recognized as a critical modulator of the initiation, progression, metastasis, and therapeutic resistance of various cancers. Cancer-associated fibroblasts (CAFs), the predominant stromal cell population within the TME, play pivotal roles in these processes through their remarkable phenotypic and functional heterogeneity. Emerging evidence underscores the diversity in the origins, phenotypes, and functions of CAFs, highlighting their ability to adaptively influence tumor biology in a context-dependent manner. CAFs facilitate cancer malignancy via multiple interconnected mechanisms, including the secretion of soluble bioactive factors, the release of exosomes, the metabolic reprogramming of tumor cells, the remodeling of the extracellular matrix (ECM), and the modulation of the immune microenvironment. CAFs have emerged as attractive and viable therapeutic targets. Recent efforts have focused on developing therapies that disrupt the protumorigenic activities of CAFs or reprogram them toward tumor-suppressive phenotypes. Several of these strategies have shown promise and are advancing into clinical trials. In this review, we comprehensively discuss recent advancements in our understanding of the heterogeneity of CAFs, elucidate their multifaceted interactions within the TME, and explore novel therapeutic strategies targeting CAFs across various cancer types. Our review aims to foster the translation of preclinical insights into clinically effective interventions targeting CAFs.

> **中文摘要：**
> 肿瘤微环境（TME）日益被认为是多种癌症在发生、进展、转移及治疗耐药性中的关键调节因素。癌相关成纤维细胞（CAF）作为TME中主要的基质细胞群，在这些过程中通过其显著的表型和功能异质性发挥核心作用。新的证据强调了CAF在起源、表型和功能方面的多样性，凸显了它们能够在依赖环境的情况下适应性地影响肿瘤生物学。CAF通过多种相互关联的机制促进癌症恶性进展，包括分泌可溶性生物活性因子、释放外泌体、重塑肿瘤细胞代谢、改造细胞外基质（ECM）以及调节免疫微环境。CAF已成为具有吸引力且可行的治疗靶点。近期研究重点是开发能够干扰CAF促肿瘤活性或将其重编程为抑瘤表型的疗法。其中若干策略已显示出良好前景，并正在推进至临床试验阶段。在本综述中，我们全面探讨了近年来对CAF异质性的认识进展，阐明其在TME中的多层面相互作用，并探索针对CAF的多种新型治疗策略，涵盖多种癌症类型。本综述的目标是促进将前期实验性研究成果转化为临床上有效的CAF靶向干预方案。

### 第二部分 AI 大师评价

本研究综述系统总结了癌相关成纤维细胞（CAF）在肿瘤微环境中的异质性及其促癌作用机制，重点分析了CAF通过多途径与肿瘤细胞及免疫环境的交叉调控。文章强调CAF是多靶点、具可塑性的研究热点，并提出靶向其功能重编程的治疗新思路。其创新性在于综合不同层面（起源、信号、代谢、免疫）的CAF研究进展，为精准抗肿瘤策略提供了方向。但当前挑战仍在于异质性定义及临床转化的复杂性。

---

## 14. 靶向肿瘤细胞内在的 ITGB2 轴可抑制黑色素瘤进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413567)
**期刊：** Molecular cancer
**PMID：** 41413567
**DOI：** 10.1186/s12943-025-02527-z

### 第一部分 原文与翻译

**英文原标题：** Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression.

> **英文摘要：**
> BACKGROUND: ITGB2 is a critical integrin mediator of immune cell activation and trafficking. Its expression has been claimed as exclusive to hematopoietic cells. Consequently, the significance of cancer cell-intrinsic ITGB2 in solid tumor progression and therapy has not been rigorously evaluated.
> 
> METHODS: We leveraged single-cell and bulk RNA sequencing, real-time quantitative PCR, multiplex immunofluorescence, flow cytometry, immunoblotting, and intercellular adhesion molecule (ICAM)-1-dependent adhesion and proliferation assays to uncover melanoma cell-intrinsic ITGB2 functional expression, association with clinical tumor progression, activation, protumorigenic signaling, adhesive and proliferative functions utilizing patient melanoma biospecimens, established human and murine melanoma lines. In vivo tumorigenicity studies in immunocompromised NOD/SCID interleukin-2 receptor γ chain null (NSG), immunocompetent wildtype, and Icam1 knockout (KO) C57BL/6 mice were performed to dissect melanoma-ITGB2 downstream pathway activity and functions in tumor growth and metastasis. The cancer cell-intrinsic ITGB2 axis was targeted using CRISPR/Cas9-based Itgb2 KO, blocking ITGB2 antibodies, ITGB2-activating CD44 crosslinking, and pharmacologic inhibition of ITGB2-dependent Wnt signaling using LGK974, zamaporvint, and FDA-approved pyrvinium pamoate repurposed for cancer therapy.
> 
> RESULTS: This work demonstrates nonhematopoietic expression and protumorigenic functions of ITGB2 intrinsic to melanoma cells. Tumor cell-ITGB2 mediated adhesion to ICAM-1, promoted cancer progression in preclinical melanoma models, was enriched in clinical metastatic versus primary melanomas or benign nevi, and predicted sentinel lymph node metastasis in patients with primary disease. Consistently, inhibition of melanoma cell-intrinsic ITGB2 using blocking antibodies or Itgb2 gene KO potently suppressed ICAM-1-mediated melanoma cell adhesion, tumor growth, and metastatic dissemination. Melanoma cell-ITGB2:ICAM-1 interaction activated downstream Wnt signaling, the pharmacologic inhibition of which suppressed melanoma-ITGB2-mediated tumorigenesis.
> 
> CONCLUSIONS: This work overturns the longstanding paradigm that ITGB2 is restricted to leukocytes by discovering a tumor cell-intrinsic ITGB2:ICAM-1:Wnt protumorigenic axis as a bona fide cancer therapeutic target in melanoma.

> **中文摘要：**
> 背景：ITGB2 是免疫细胞激活与迁移的重要整合素介质。其表达长期以来被认为仅限于造血细胞。因此，肿瘤细胞内在 ITGB2 在实体瘤进展及治疗中的意义尚未得到严格评估。
> 
> 方法：本研究利用单细胞及整体 RNA 测序、实时定量 PCR、多重免疫荧光、流式细胞术、免疫印迹以及依赖细胞间黏附分子（ICAM）-1 的黏附与增殖实验，揭示了黑色素瘤细胞内在 ITGB2 的功能性表达、其与临床肿瘤进展、活化、促肿瘤信号、黏附与增殖功能之间的关联。研究材料包括患者黑色素瘤生物样本及已建立的人和小鼠黑色素瘤细胞系。在体研究中，利用免疫缺陷型 NOD/SCID γ 链缺失（NSG）小鼠、免疫健全野生型及 Icam1 基因敲除（KO）C57BL/6 小鼠，分析黑色素瘤 ITGB2 下游通路活性及其在肿瘤生长与转移中的功能。研究通过 CRISPR/Cas9 介导的 Itgb2 基因敲除、ITGB2 阻断抗体、ITGB2 激活性 CD44 交联，以及药物学抑制 ITGB2 依赖的 Wnt 信号通路（使用 LGK974、zamaporvint 及经 FDA 批准的吡维莫司双潘酸盐等药物）来靶向癌细胞内在的 ITGB2 轴。
> 
> 结果：该研究表明，ITGB2 在黑色素瘤细胞中存在非造血来源的表达，并具有促肿瘤作用。肿瘤细胞 ITGB2 介导与 ICAM-1 的黏附，在黑色素瘤临床转移性样本中较原发性黑色素瘤或良性痣显著富集，并可预测原发病患者的前哨淋巴结转移。相应地，通过 ITGB2 阻断抗体或 Itgb2 基因敲除抑制黑色素瘤细胞内在 ITGB2，能够显著抑制 ICAM-1 介导的黏附、肿瘤生长及转移扩散。黑色素瘤细胞 ITGB2：ICAM-1 相互作用可激活下游 Wnt 信号通路，而药理学阻断该通路可有效抑制 ITGB2 介导的肿瘤形成。
> 
> 结论：本研究推翻了“ITGB2 仅限于白细胞表达”的长期观点，发现了一个由肿瘤细胞内在 ITGB2：ICAM-1：Wnt 构成的促肿瘤轴，为黑色素瘤提供了新的、确证的治疗靶点。

### 第二部分 AI 大师评价

本研究揭示 ITGB2 不仅存在于免疫或造血细胞中，还在黑色素瘤细胞内具有促肿瘤作用，突破了传统认知。作者综合采用单细胞转录组、多种体外功能实验及小鼠模型，系统阐明了 ITGB2：ICAM-1：Wnt 信号轴在肿瘤黏附、增殖与转移中的关键作用。结果显示，靶向 ITGB2 可有效阻断黑色素瘤进展，提示其为潜在治疗靶点。研究的创新性在于首次确立 ITGB2 的肿瘤细胞内在功能，但仍需进一步验证其在临床人群中的可转化性与安全性。

---

## 15. WTAP/YTHDF1 介导的 m⁶A 修饰调控 PXDN，通过细胞外基质重塑激活 PI3K/AKT 信号通路，促进鼻咽癌进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413560)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41413560
**DOI：** 10.1186/s13046-025-03609-y

### 第一部分 原文与翻译

**英文原标题：** PXDN regulated by WTAP/YTHDF1-mediated mA modification activates PI3K/AKT signaling pathway through extracellular matrix remodeling to promote progression in nasopharyngeal carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要暂无可用内容。

### 第二部分 AI 大师评价

该研究聚焦于鼻咽癌的表观转录调控机制，揭示 m⁶A 修饰关键蛋白 WTAP 和 YTHDF1 对 PXDN 的调控作用。研究提出 PXDN 通过细胞外基质重塑激活 PI3K/AKT 信号通路，从而促进癌症进展。这一关联连接了 m⁶A 表观修饰与肿瘤微环境之间的分子机制，具有创新意义。若摘要缺失，仍可推测研究在机制层面提供了潜在治疗靶点，但具体实验设计与验证尚需进一步说明。

---

## 16. 靶向 OxLDL 介导的 CD36⁺ 癌相关成纤维细胞重编程可增强骨肉瘤中的 PD-1 免疫治疗效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413558)
**期刊：** Molecular cancer
**PMID：** 41413558
**DOI：** 10.1186/s12943-025-02516-2

### 第一部分 原文与翻译

**英文原标题：** Targeting OxLDL-mediated CD36 + CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma.

> **英文摘要：**
> BACKGROUND: Osteosarcoma demonstrates limited responsiveness to PD-1 blockade, largely due to its immunosuppressive tumor microenvironment (TME). The specific mechanisms by which cancer-associated fibroblasts (CAFs) contribute to immunosuppression in osteosarcoma are not fully understood.
> 
> METHODS: We performed single-cell RNA sequencing (scRNA-seq) on osteosarcoma tissues from patients treated with neoadjuvant chemotherapy and anti-PD-1 therapy to investigate the tumor microenvironment. Cellular composition, gene expression programs, and signaling pathways were analyzed. Functional assays, pull-down and PLA-flow binding validation, and in vivo mouse models were used to dissect the mechanisms by which CAF-derived factors influence CD8⁺ T cell function and contribute to immunotherapy response.
> 
> RESULTS: We identified a subpopulation of CD36⁺ CAFs, characterized by adaptive uptake of oxidized low-density lipoprotein (OxLDL) and activation of the PPARG-FABP4 axis. This metabolic program promoted ANGPTL4 secretion, which bound integrin on CD8⁺ T cells and activated the JAK2-STAT3 pathway, leading to T cell exhaustion and impaired effector function. In vivo, administration of VitE effectively scavenged OxLDL, reprogrammed the TME, enhanced CD8⁺ T cell infiltration, and synergized with PD-1 blockade to improve tumor control.
> 
> CONCLUSIONS: CD36⁺ CAFs drive immunosuppressive metabolic reprogramming via the OxLDL-PPARG-ANGPTL4 axis, promoting CD8⁺ T cell exhaustion and resistance to immunotherapy in osteosarcoma. Targeting this pathway with VitE alleviated CAF-mediated immune suppression and enhanced PD-1 blockade responses in preclinical models, providing a rationale for metabolism-based combinatorial strategies in osteosarcoma.

> **中文摘要：**
> 背景：骨肉瘤对 PD-1 阻断治疗的反应性有限，主要归因于其免疫抑制性的肿瘤微环境（TME）。癌相关成纤维细胞（CAF）在骨肉瘤免疫抑制中的具体作用机制尚未被充分阐明。
> 
> 方法：本研究对接受新辅助化疗及抗 PD-1 治疗的骨肉瘤患者组织进行了单细胞 RNA 测序（scRNA-seq），以探究其肿瘤微环境。研究分析了细胞组成、基因表达程序及信号通路。通过功能实验、pull-down 与 PLA-flow 结合验证实验以及体内小鼠模型，解析了 CAF 来源因子如何影响 CD8⁺ T 细胞功能并参与免疫治疗反应的机制。
> 
> 结果：我们鉴定出一类 CD36⁺ CAF 亚群，其特征为对氧化低密度脂蛋白（OxLDL）的适应性摄取以及 PPARG-FABP4 轴的激活。该代谢程序促进了 ANGPTL4 的分泌，ANGPTL4 可与 CD8⁺ T 细胞上的整合素结合并激活 JAK2-STAT3 通路，从而造成 T 细胞耗竭及效应功能受损。在体内实验中，维生素 E（VitE）处理可有效清除 OxLDL，重塑肿瘤微环境，增强 CD8⁺ T 细胞浸润，并与 PD-1 阻断协同以改善肿瘤控制。
> 
> 结论：CD36⁺ CAF 通过 OxLDL-PPARG-ANGPTL4 轴诱导免疫抑制性代谢重编程，促进 CD8⁺ T 细胞耗竭及免疫治疗耐受。靶向该通路的 VitE 可缓解 CAF 介导的免疫抑制，并在临床前模型中增强 PD-1 阻断疗效，为骨肉瘤代谢联合免疫治疗提供了理论依据。

### 第二部分 AI 大师评价

本研究聚焦于骨肉瘤免疫治疗抵抗问题，揭示了 CD36⁺ 癌相关成纤维细胞通过 OxLDL-PPARG-ANGPTL4 代谢信号轴介导的免疫抑制机制。通过单细胞测序与多层次功能验证，研究清晰展示了 CAF 代谢重编程对 CD8⁺ T 细胞功能的负向调控。维生素 E 被发现能逆转这一过程并与 PD-1 阻断产生协同效应。该研究为骨肉瘤免疫治疗策略提供了创新性的代谢干预思路，但仍需进一步临床验证其安全性与有效性。

---

## 17. 微卫星稳定型结直肠癌的免疫相关去泛素化谱揭示 USP7 作为潜在的免疫治疗靶点。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413544)
**期刊：** Molecular cancer
**PMID：** 41413544
**DOI：** 10.1186/s12943-025-02502-8

### 第一部分 原文与翻译

**英文原标题：** Immune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target.

> **英文摘要：**
> The efficacy of immune checkpoint inhibitors (ICIs) in microsatellite stable colorectal cancer (MSS CRC) remains limited, highlighting an urgent need for predictive biomarkers. Through multi-omics analysis, we identified two novel MSS CRC subtypes, termed DUB-H and DUB-L. The DUB-L subtype exhibited an inflamed tumor immune microenvironment, a superior response to immune therapy, and better recurrence-free survival (RFS) compared to DUB-H. The classifier gene USP7 was selected as a gene of interest due to its specific expression profile, which is highly expressed in MSS CRC but not in microsatellite instability-high (MSI-H) tumors, and strongly correlated with suppressed immune infiltration. Large-scale clinical analyses confirmed associations between high USP7 expression, microsatellite stability, specific consensus molecular subtypes (CMS), and unfavorable prognosis. Single-cell analysis and multiplex immunofluorescence validated an immune-desert phenotype in USP7-high MSS tumors. Mechanistically, USP7 knockdown in MSS CRC cells enhances the secretion of T-cell-recruiting chemokines (CXCL9/10/11), promoting CD8⁺ T cell recruitment and cytotoxicity in vitro. In vivo experiments demonstrated that USP7 blockade enhanced the efficacy of anti-PD-1 treatment in MSS CRC models by remodeling the tumor immune microenvironment, increasing infiltration and function of CD8⁺ T and NK cells. Consistently, low USP7 expression is associated with a better response to anti-PD-1 therapy. Overall, we propose a novel DUB-based classification system for MSS CRC and demonstrate that targeting USP7 may overcome immunotherapy resistance by converting immunologically "cold" tumors into "hot" ones.

> **中文摘要：**
> 免疫检查点抑制剂（ICIs）在微卫星稳定型结直肠癌（MSS CRC）中的疗效仍然有限，这凸显了对预测性生物标志物的迫切需求。通过多组学分析，我们鉴定出两种新的 MSS CRC 亚型，命名为 DUB-H 和 DUB-L。与 DUB-H 亚型相比，DUB-L 亚型表现出炎症型肿瘤免疫微环境、对免疫治疗的更好应答以及更优的无复发生存期（RFS）。分类基因 USP7 因其特异的表达特征而被选为关注基因，该基因在 MSS CRC 中高表达，而在高微卫星不稳定型（MSI-H）肿瘤中则不高表达，并且与免疫浸润受抑密切相关。大规模临床分析证实了高 USP7 表达与微卫星稳定性、特定的共识分子亚型（CMS）以及不良预后之间的关联。单细胞分析及多重免疫荧光验证了高 USP7 表达的 MSS 肿瘤呈现免疫“沙漠”表型。从机制上看，下调 MSS CRC 细胞中的 USP7 可增强 T 细胞趋化因子（CXCL9/10/11）的分泌，从而在体外促进 CD8⁺ T 细胞的募集和细胞毒活性。体内实验表明，通过重塑肿瘤免疫微环境，USP7 阻断可增强抗 PD-1 治疗在 MSS CRC 模型中的疗效，增加 CD8⁺ T 细胞和 NK 细胞的浸润及功能。与此一致，低 USP7 表达与更好的抗 PD-1 治疗反应相关。总体而言，我们提出了一种基于 DUB 的 MSS CRC 新分类体系，并表明靶向 USP7 可能通过将免疫“冷”肿瘤转化为“热”肿瘤来克服免疫治疗耐受性。

### 第二部分 AI 大师评价

本研究通过多组学整合分析揭示了微卫星稳定型结直肠癌的去泛素化特征谱，定义了 DUB-H 和 DUB-L 两个新的亚型，为 MSS CRC 的免疫分层提供了新思路。研究确定 USP7 是影响免疫微环境的重要分子，高表达与免疫抑制及不良预后相关。功能实验表明，USP7 下调可增强 T 细胞浸润并提高抗 PD-1 疗效，提示其作为免疫治疗靶点的潜力。该研究创新性地提出 DUB 基于分型体系，但仍需临床转化研究验证其可行性与安全性。

---

## 18. 乳酸线粒体氧化驱动转移性乳腺癌的干性潜能。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413384)
**期刊：** Nature communications
**PMID：** 41413384
**DOI：** 10.1038/s41467-025-67091-y

### 第一部分 原文与翻译

**英文原标题：** Lactate mitochondrial oxidation drives stemness potential in metastatic breast cancer.

> **英文摘要：**
> Metastatic cancer cells, originating from cancer stem cells with metastatic capacity, utilize nutrient flexibility to navigate the challenges of the metastatic cascade. However, the nutrient required to maintain the stemness potentials of metastatic cancer cells remains unclear. Here, we reveal that metastatic breast cancer cells sustain stemness and initiate metastasis upon detachment by taking up and oxidizing lactate. In detached metastasizing breast cancer cells, lactate is incorporated into the tricarboxylic acid cycle, boosting oxidative phosphorylation, and promoting the stemness potentials via α-KG-DNMT3B-mediated SOX2 hypomethylation. Moreover, lactate is taken up and oxidized in mitochondria by the CD147/MCT1/LDHB complex, which correlates with stemness potentials and tumor metastasis in patients with breast cancer. An intracellularly expressed single-chain variable fragment targeting mitochondrial CD147 (mito-CD147 scFv) effectively disrupts the mitochondrial CD147/MCT1/LDHB complex, inhibits lactate-induced stemness potential, depletes circulating breast cancer cells, and reduces metastatic burden, suggesting promising clinical applications in reducing lactate-fueled metastasis.

> **中文摘要：**
> 转移性癌细胞起源于具有转移能力的癌症干细胞，它们利用营养物质的灵活性以应对转移级联过程中的种种挑战。然而，维持转移性癌细胞干性潜能所需的关键营养物质仍不清楚。本研究揭示，转移性乳腺癌细胞在脱离后通过摄取并氧化乳酸以维持干性并启动转移。在脱离的转移性乳腺癌细胞中，乳酸被纳入三羧酸循环，增强氧化磷酸化，并通过α-KG-DNMT3B介导的SOX2低甲基化促进干性潜能。此外，乳酸在线粒体中由CD147/MCT1/LDHB复合物摄取并氧化，这一过程与乳腺癌患者的干性潜能及肿瘤转移密切相关。靶向线粒体CD147的细胞内表达单链可变片段（mito-CD147 scFv）可有效破坏线粒体CD147/MCT1/LDHB复合物，抑制乳酸诱导的干性潜能，清除循环中的乳腺癌细胞，并降低转移负担，提示其在减少乳酸驱动的转移中具有潜在临床应用价值。

### 第二部分 AI 大师评价

该研究旨在揭示乳酸代谢在转移性乳腺癌干性维持与转移过程中的关键作用。作者首次明确指出，乳酸通过在线粒体内氧化并参与TCA循环，促进SOX2低甲基化，从而增强癌细胞干性潜能。其发现CD147/MCT1/LDHB复合物在乳酸氧化中的核心作用，并通过干预性分子（mito-CD147 scFv）验证了潜在的治疗策略。研究创新性地将代谢通路与表观遗传调控联系起来，但仍需进一步验证其在临床应用中的安全性与普适性。

---

## 19. 肿瘤病毒特异性TCR转基因体内模型中功能失调的CD4 T细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413276)
**期刊：** Nature communications
**PMID：** 41413276
**DOI：** 10.1038/s41467-025-67588-6

### 第一部分 原文与翻译

**英文原标题：** Dysfunctional CD4 T cells in an oncovirus-specific TCR-transgenic in vivo model.

> **英文摘要：**
> T cell exhaustion has been implicated in cancer and infectious diseases. In this study, we report a novel mouse model, "MolT-II", with T cells expressing a transgenic T cell receptor (TCR) specific for a Moloney virus envelope-derived, MHC class II-presented peptide epitope. Characterization of MolT-II CD4 T cells revealed that they are dysfunctional, showing severely impaired effector functions, reduced proliferation and increased baseline expression of co-inhibitory receptors such as PD-1, LAG-3 and CTLA-4, likely due to chronic exposure to a self-antigen. We further show that epitope-specific peptide vaccination combined with immune checkpoint blockade is able to restore the function of MolT-II CD4 T cells in vivo, associated with enhanced tumor control in mice. The MolT-II mouse strain thus represents an in vivo model for reversible CD4 T cell dysfunction, allowing the study of the role of CD4 T cell regulation in cancer, mechanisms underlying CD4 T cell dysfunction and exhaustion, and novel immunomodulatory therapies aiming to rescue dysfunctional T cells.

> **中文摘要：**
> T细胞衰竭已被认为与癌症和感染性疾病有关。在本研究中，我们报告了一种新型小鼠模型“MolT-II”，其T细胞表达一种转基因T细胞受体（TCR），该受体特异性识别由Moloney病毒包膜来源的、经MHC II类分子呈递的肽表位。对MolT-II CD4 T细胞的特征分析显示，这些细胞存在功能障碍，表现为效应功能严重受损、增殖能力下降，以及PD-1、LAG-3和CTLA-4等共抑制受体的基线表达上调，这可能是长期暴露于自身抗原所致。我们进一步显示，表位特异性肽疫苗联合免疫检查点抑制可在体内恢复MolT-II CD4 T细胞的功能，并与小鼠肿瘤控制的增强相关。因此，MolT-II小鼠品系代表了一种可逆性CD4 T细胞功能障碍的体内模型，为研究CD4 T细胞在癌症中的调控作用、其功能失调与衰竭机制，以及旨在恢复功能失调T细胞的新型免疫调节治疗提供了工具。

### 第二部分 AI 大师评价

该研究建立了一个创新性的MolT-II小鼠模型，用于模拟并研究肿瘤病毒特异性CD4 T细胞功能失调的可逆性机制。通过描述其效应功能缺陷与共抑制分子上调，该模型揭示了慢性抗原刺激导致的T细胞衰竭特征。作者进一步通过表位疫苗联合免疫检查点阻断实验，验证了功能可被恢复并改善肿瘤控制的潜能。该模型为探索CD4 T细胞在免疫抑制与肿瘤免疫治疗中的作用提供了重要工具，但其人类疾病相关性及长期免疫动态仍需进一步研究。

---

## 20. 在人类遗传变异与小鼠基因组间的计算预测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413243)
**期刊：** Nature biotechnology
**PMID：** 41413243
**DOI：** 10.1038/s41587-025-02925-0

### 第一部分 原文与翻译

**英文原标题：** Computational prediction of human genetic variants in the mouse genome.

> **英文摘要：**
> The design of genetically engineered mouse models would benefit from a computational pipeline to predict mouse genetic variants that mirror the sequence and functional effects of human disease variants. Here we present H2M (human-to-mouse), which achieves this by integrating mouse-to-human and paralog-to-paralog variant mapping analyses with genome-editing tools. We provide a database containing >3 million human-mouse equivalent mutation pairs and base-editing and prime-editing libraries to engineer 4,944 variant pairs.

> **中文摘要：**
> 遗传工程小鼠模型的设计亟需一种计算流程，以预测能在序列和功能效应上反映人类疾病变异的小鼠遗传变异。我们在此提出H2M（human-to-mouse），该方法通过整合小鼠与人类、以及旁系同源基因之间的变异映射分析，并结合基因组编辑工具，实现这种预测。我们提供了一个包含超过三百万对人-鼠等效突变的数据集，以及用于构建4,944对变异的碱基编辑和引导编辑文库。

### 第二部分 AI 大师评价

本研究旨在通过计算方法实现人类与小鼠遗传变异的系统性映射，优化疾病模型的构建。作者开发的H2M工具将跨物种变异映射与基因编辑平台相结合，建立了高质量的大规模突变对数据库，显著提升了小鼠遗传学研究的效率与可扩展性。该方法在疾病机制研究和模型开发中具有广泛潜力，其创新在于系统整合了多层级变异信息。局限性可能包括对特定基因组区域或复杂调控变异的预测准确度仍待进一步验证。

---

## 21. 缺氧诱导的VEGF分泌促进了对双特异性T细胞连接剂的耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413213)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41413213
**DOI：** 10.1038/s41392-025-02505-3

### 第一部分 原文与翻译

**英文原标题：** Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.

> **英文摘要：**
> Bispecific T-cell Engagers (BITEs) are a novel form of immunotherapy that overcome a deficiency of immune checkpoint inhibitors (ICI) by targeting a preidentified tumor associated antigen and redirecting a polyclonal population of effector T-cells against the tumor. High grade serous ovarian cancer is a lethal disease in the recurrent setting and has not been amenable to ICI therapy. MUC16/CA125 is overexpressed in high grade serous ovarian cancer. BITEs targeting the tumor-retained portion of MUC16/CA125 have recently been described and are in early-phase clinical trials. To identify mechanisms of resistance to BITEs, we collected serum, peripheral blood mononuclear cells, and ascites samples from patients with disease progression on MUC16-directed bispecific antibodies. Analysis of these samples showed downregulation of MUC16/CA125, elevated secretion of VEGF, and epithelial-to-mesenchymal transition in tumor cells. Interestingly, hypoxia was determined to be a driver of these changes. These findings were prospectively validated in ovarian cancer cell lines with CRISPR/Cas9 knockout of MUC16/CA125 and VEGF. Peripheral blood mononuclear cells from patients with disease progression were capable of effective cytolysis ex vivo, suggesting that resistance to therapy was primarily tumor driven. Restoration of MUC16/CA125 expression did not restore cytotoxicity in the presence of increased VEGF secretion. Combination treatment with a VEGF inhibitor rescued cytotoxicity in hypoxia-conditioned ovarian cancer cell lines with preserved target antigen expression. Collectively, these data outline a link between hypoxia and the development of resistance to BITEs and posits inhibition of VEGF inhibition as a potentially important therapeutic intervention.

> **中文摘要：**
> 双特异性T细胞连接剂（BITEs）是一种新型免疫治疗形式，通过靶向已确定的肿瘤相关抗原并重新定向多克隆效应T细胞群体攻击肿瘤，从而克服免疫检查点抑制剂（ICI）的不足。高级别浆液性卵巢癌在复发情况下是一种致命性疾病，且对ICI治疗不敏感。MUC16/CA125在高级别浆液性卵巢癌中过度表达。最近已报道了靶向MUC16/CA125肿瘤保留部分的BITEs，并进入早期临床试验阶段。为识别BITEs的耐药机制，我们收集了在MUC16靶向双特异性抗体治疗后疾病进展患者的血清、外周血单个核细胞和腹水样本。对这些样本的分析显示MUC16/CA125的下调、VEGF分泌的增加以及肿瘤细胞上皮-间质转化的发生。有趣的是，缺氧被确定为这些变化的驱动因素。这些发现通过在卵巢癌细胞系中利用CRISPR/Cas9敲除MUC16/CA125和VEGF进行了前瞻性验证。来自疾病进展患者的外周血单个核细胞在体外仍具有有效的细胞溶解能力，提示耐药性主要由肿瘤驱动。恢复MUC16/CA125的表达在VEGF分泌升高的条件下并不能恢复细胞毒性。将VEGF抑制剂与治疗联合使用可在缺氧条件下且保留靶抗原表达的卵巢癌细胞系中恢复细胞毒性。总体而言，这些数据揭示了缺氧与BITEs耐药发展的关联，并提出VEGF抑制可能是一种重要的治疗干预策略。

### 第二部分 AI 大师评价

本研究旨在阐明卵巢癌对双特异性T细胞连接剂（BITE）治疗产生耐药的分子机制。作者通过临床样本和体外细胞模型，发现缺氧可诱导VEGF分泌上调、MUC16/CA125下调及上皮-间质转化过程，从而导致肿瘤获得免疫逃逸特性。研究进一步证实联合使用VEGF抑制剂可恢复细胞毒性作用，提示VEGF通路在BITE耐药中起关键调控作用。该工作为提高BITE治疗效果提供了新的生物学依据和潜在联合策略，但仍需更多临床验证。

---

## 22. 地塞米松驱动的巨噬细胞再极化与三阴性乳腺癌侵袭性增强相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413093)
**期刊：** Cell death & disease
**PMID：** 41413093
**DOI：** 10.1038/s41419-025-08363-9

### 第一部分 原文与翻译

**英文原标题：** Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness.

> **英文摘要：**
> Glucocorticoids (GCs) are known for their anti-inflammatory potential, which includes the macrophage polarization into an anti-inflammatory and tissue remodeling state. GCs are routinely co-administered to cancer patients to alleviate the side effects of chemotherapy. However, it is not well known if GCs can modulate tumor-associated macrophages (TAMs) to promote tumor progression. Here, we show that dexamethasone (DEX) induces dose-dependent differentiation of THP-1 monocyte-derived anti-tumorigenic (M1) macrophages into pro-tumorigenic (M2-like) macrophages, even in the presence of M1 cues, and that DEX can repolarize fully differentiated M1 macrophages into an M2-like state. These macrophages have a cytokine profile similar to the pro-tumorigenic (M2) macrophages and can stimulate the proliferation and invasion of triple-negative breast cancer (TNBC) cells in vitro. DEX treatment of an orthotopic mouse model of TNBC attenuated paclitaxel-mediated tumor growth inhibition, increased M2-like TAMs in primary tumors, and enhanced lung metastasis. Transcriptomic analysis of DEX-treated M1 macrophages revealed not only transcriptomic overlap with M2 macrophages, but also with human breast cancer TAM transcriptomic data, and further to a specific TAM signature associated with aggressive estrogen receptor-negative breast cancer. Our study illustrates a remarkable macrophage repolarization plasticity upon DEX exposure that can promote tumorigenesis, warranting care in prescribing high doses of GCs to breast cancer patients, especially to those considered for chemotherapy.

> **中文摘要：**
> 糖皮质激素（GCs）以其抗炎潜能而闻名，其中包括将巨噬细胞极化为抗炎和组织重塑状态。GCs常规与化疗药物联合用于癌症患者，以缓解化疗的副作用。然而，目前尚不清楚GCs是否能够调节肿瘤相关巨噬细胞（TAMs）以促进肿瘤进展。在本研究中，我们发现地塞米松（DEX）可剂量依赖性地诱导THP-1单核细胞来源的抗肿瘤（M1）型巨噬细胞向促肿瘤（M2样）巨噬细胞分化，即使在M1诱导信号存在的情况下，DEX仍可使已完全分化的M1型巨噬细胞再极化为M2样状态。这些巨噬细胞的细胞因子谱与促肿瘤（M2）型巨噬细胞相似，且能在体外促进三阴性乳腺癌（TNBC）细胞的增殖与侵袭。对TNBC正位小鼠模型施用DEX可削弱紫杉醇介导的肿瘤生长抑制，增加原发肿瘤中的M2样TAMs，并增强肺转移。对DEX处理的M1型巨噬细胞进行转录组分析显示，它们不仅与M2型巨噬细胞的转录组有重叠，还与人类乳腺癌TAM的转录组数据重叠，并进一步与与侵袭性雌激素受体阴性乳腺癌相关的特定TAM特征相联系。本研究揭示了DEX暴露下巨噬细胞显著的再极化可塑性，这种变化可促进肿瘤发生，提示在为乳腺癌患者（尤其是接受化疗者）开具高剂量GCs时应谨慎。

### 第二部分 AI 大师评价

该研究旨在探讨地塞米松对巨噬细胞极化及乳腺癌进展的影响。研究采用细胞与动物模型相结合的方式，发现地塞米松可诱导M1型巨噬细胞转化为促肿瘤M2样表型，并在三阴性乳腺癌模型中增强肿瘤侵袭性与转移。转录组分析揭示了与人类乳腺癌TAM相似的基因表达特征，丰富了对GCs免疫调控作用的理解。研究创新地将化疗辅助用药与肿瘤免疫微环境重编程相联系，同时提示临床GCs应用可能存在潜在风险。

---

## 23. 肽酰-tRNA水解酶2是雌性小鼠产褥期心肌病伴心力衰竭的负向调控因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413062)
**期刊：** Nature communications
**PMID：** 41413062
**DOI：** 10.1038/s41467-025-67852-9

### 第一部分 原文与翻译

**英文原标题：** Peptidyl-tRNA hydrolase 2 is a negative regulator of peripartum cardiomyopathy with heart failure in female mice.

> **英文摘要：**
> The peptidyl-tRNA hydrolase 2 (PTRH2, Bit-1, BIT1) gene plays a pro-survival role during development with loss of function gene mutations causing congenital infantile multisystem disease (IMNEPD). In wild-type female mice hearts, Ptrh2 protein levels significantly increase during pregnancy and decrease postpartum, demonstrating a protective role in response to pregnancy-initiated cardiac stresses. Peripartum cardiomyopathy (PPCM) is due to dysregulated protective signaling in the pregnant heart. The genetic and molecular mechanisms underlying PPCM remain poorly defined with no specific therapies. Here, we engineered a cardiac-specific Ptrh2 knockout (Ptrh2-CKO) mouse and show these maternal mice develop left ventricular systolic dysfunction, exhibit high rates of postpartum heart failure, and model key features of human PPCM. Infusion of a caspase 3-specific inhibitor attenuated the PPCM phenotype. Collectively, our findings demonstrate Ptrh2 is a negative regulator of pregnancy-induced cardiac stresses by activating pro-survival signals and blocking apoptotic signals, suggesting Ptrh2 may be a therapeutic target for the treatment of PPCM.

> **中文摘要：**
> 肽酰-tRNA水解酶2（PTRH2，也称Bit-1或BIT1）基因在发育过程中发挥促存活作用，其功能缺失突变可导致先天性婴儿多系统疾病（IMNEPD）。在野生型雌性小鼠的心脏中，Ptrh2蛋白水平在妊娠期显著升高，而在产后下降，显示其在应对妊娠诱导的心脏应激中具有保护作用。产褥期心肌病（PPCM）是由于妊娠期心脏保护信号通路失调所致。PPCM的遗传和分子机制目前仍不清楚，且尚无特异性治疗方法。本研究构建了心脏特异性Ptrh2基因敲除（Ptrh2-CKO）小鼠，发现这些母鼠出现左心室收缩功能障碍，产后心力衰竭发生率显著升高，并重现了人类PPCM的关键特征。注入半胱天冬酶3特异性抑制剂可减轻PPCM表型。综上，研究结果表明，Ptrh2通过激活促存活信号并抑制凋亡信号，在妊娠诱导的心脏应激中充当负向调控因子，提示Ptrh2可能成为PPCM治疗的潜在靶点。

### 第二部分 AI 大师评价

本文通过建立心脏特异性Ptrh2基因敲除小鼠模型，系统揭示了Ptrh2在妊娠相关心脏应激反应中的关键保护作用。研究发现Ptrh2缺失会导致母鼠出现与人类产褥期心肌病类似的心力衰竭表型，并可通过抑制凋亡信号部分逆转该现象。该工作创新性地将发育相关存活因子与产褥期心肌病发病机制相联系，为PPCM靶向治疗提供了新的分子依据，但仍需进一步研究以验证其临床转化潜力。

---

## 24. HHIPL2通过增强HNRNPC介导的HNF1A mRNA稳定性，正向调控Hedgehog信号通路以促进非小细胞肺癌进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413056)
**期刊：** Cell death & disease
**PMID：** 41413056
**DOI：** 10.1038/s41419-025-08331-3

### 第一部分 原文与翻译

**英文原标题：** HHIPL2 positively governs Hedgehog signaling to accelerate non-small cell lung cancer progression via enhancing HNRNPC-mediated HNF1A mRNA stabilization.

> **英文摘要：**
> Sonic Hedgehog signaling is aberrantly activated in non-small cell lung cancer (NSCLC). However, the regulatory molecules of Sonic Hedgehog signaling during NSCLC development are still largely unknown. Here, we demonstrated that HHIP Like 2 (HHIPL2) is a crucial Sonic Hedgehog signaling regulator, accelerating NSCLC progression via positively governing Sonic Hedgehog signaling. Clinically, HHIPL2 is highly expressed in NSCLC and indicates a poor prognosis. Consistently, via depletion or gain of HHIPL2 in vivo and in vitro, we identified its oncogenic role in NSCLC proliferation and metastasis. Mechanistically, HHIPL2 interacted with the RNA-binding protein HNRNPC to alter its nucleo-cytoplasmic translocation. HHIPL2-regulated HNRNPC accumulation in the cytoplasm promoted the mRNA stability of HNF1A, a transcription factor for SHH, which subsequently enhanced the Sonic Hedgehog signaling activity to facilitate NSCLC progression. Furthermore, we discovered that triptolide (TPL), an HNF1A inhibitor, impeded HHIPL2-mediated Sonic Hedgehog signaling activation and NSCLC malignancy. Therefore, our findings not only uncover a previously unrecognized role for HHIPL2 in regulating the Sonic Hedgehog signaling pathway but also highlight a novel HHIPL2/HNRNPC/HNF1A axis as an attractive target for NSCLC therapy.Schematic diagram (created by Figdraw.com) showing that HHIPL2 positively governs Hedgehog signaling to accelerate NSCLC progression via enhancing HNRNPC-mediated HNF1A mRNA stabilization.

> **中文摘要：**
> Sonic Hedgehog信号通路在非小细胞肺癌（NSCLC）中异常激活。然而，在NSCLC发展过程中，Sonic Hedgehog信号的调控分子仍 largely 未知。在本研究中，我们证明了HHIP样蛋白2（HHIPL2）是Sonic Hedgehog信号的关键调节因子，通过正向调控该信号通路加速NSCLC的进展。在临床上，HHIPL2在NSCLC中高表达，并与预后不良相关。通过体内外敲减或过表达HHIPL2，我们一致地验证了其在NSCLC细胞增殖和转移中的致癌作用。在机制上，HHIPL2与RNA结合蛋白HNRNPC相互作用，改变其核质转运。HHIPL2调控的细胞质HNRNPC积累促进了HNF1A（一种调控SHH的转录因子）mRNA的稳定性，从而增强了Sonic Hedgehog信号活性，促进NSCLC的进展。此外，我们发现HNF1A抑制剂雷公藤内酯（TPL）可阻断HHIPL2介导的Sonic Hedgehog信号激活及NSCLC的恶性特征。因此，本研究不仅揭示了HHIPL2在调控Sonic Hedgehog信号通路中的全新作用，还强调了一条新颖的HHIPL2/HNRNPC/HNF1A轴，作为NSCLC治疗的潜在靶点。由Figdraw.com绘制的示意图展示了HHIPL2通过增强HNRNPC介导的HNF1A mRNA稳定性，正向调控Hedgehog信号以促进NSCLC进展。

### 第二部分 AI 大师评价

该研究揭示HHIPL2作为Sonic Hedgehog信号通路的重要正调控因子，在非小细胞肺癌进展中发挥促进作用。作者通过临床样本分析、体内外实验及机制探究，确定HHIPL2可通过与HNRNPC互作增强HNF1A mRNA稳定性，从而激活Hedgehog信号。研究进一步验证HNF1A抑制剂雷公藤内酯可削弱这一通路活性，提示其潜在治疗价值。该发现揭开了Hedgehog信号新型调控层面，为NSCLC治疗提供了新的分子靶点，但仍需更多临床验证以明确其转化可行性。

---

## 25. 一种小型周质蛋白通过调控DbfRS双组分系统支配霍乱弧菌的广泛生理适应反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413053)
**期刊：** Nature communications
**PMID：** 41413053
**DOI：** 10.1038/s41467-025-66735-3

### 第一部分 原文与翻译

**英文原标题：** A small periplasmic protein governs broad physiological adaptations in Vibrio cholerae via regulation of the DbfRS two-component system.

> **英文摘要：**
> Two-component signaling pathways allow bacteria to sense and respond to environmental changes, yet the sensory mechanisms of many remain poorly understood. In the pathogen Vibrio cholerae, the DbfRS two-component system controls the biofilm lifecycle, a critical process for environmental persistence and host colonization. Here, we identified DbfQ, a small periplasmic protein encoded adjacent to dbfRS, as a direct modulator of pathway activity. DbfQ directly binds the sensory domain of the histidine kinase DbfS, shifting it toward phosphatase activity and promoting biofilm dispersal. In contrast, outer membrane perturbations, caused by mutations in lipopolysaccharide biosynthesis genes or membrane-damaging antimicrobials, activate phosphorylation of the response regulator DbfR. Transcriptomic analyses reveal that DbfR phosphorylation leads to broad transcriptional changes spanning genes involved in biofilm formation, central metabolism, and cellular stress responses. Constitutive DbfR phosphorylation imposes severe fitness costs in an infection model, highlighting this pathway as a potential target for anti-infective therapeutics. We find that dbfQRS-like genetic modules are widely present across bacterial phyla, underscoring their broad relevance in bacterial physiology. Collectively, these findings establish DbfQ as a new class of periplasmic regulator that influences two-component signaling and bacterial adaptation.

> **中文摘要：**
> 双组分信号通路使细菌能够感知并响应环境变化，但许多此类通路的感受机制仍然知之甚少。在病原体霍乱弧菌中，DbfRS双组分系统调控生物膜的生命周期，这是环境持续存在与宿主定植过程中的关键环节。本文鉴定出DbfQ这一编码于dbfRS邻近区域的小型周质蛋白，作为该信号通路活性的直接调节因子。DbfQ可直接结合组氨酸激酶DbfS的感受结构域，使其活性转向磷酸酶功能，并促进生物膜解离。相反，由脂多糖生物合成基因突变或破坏膜结构的抗菌剂引起的外膜扰动，会激活反应调节蛋白DbfR的磷酸化。转录组分析显示，DbfR的磷酸化导致涉及生物膜形成、中心代谢和细胞应激反应等多类基因的广泛转录变化。在感染模型中，持续的DbfR磷酸化会造成显著的适应性代价，提示该通路可能成为抗感染治疗的潜在靶点。研究发现，dbfQRS样遗传模块在多个细菌门中普遍存在，强调了其在细菌生理学中的广泛重要性。综上所述，这些发现确立了DbfQ作为一种新型周质调节因子的地位，其能够影响双组分信号传导及细菌适应过程。

### 第二部分 AI 大师评价

本研究揭示了一种小型周质蛋白DbfQ对霍乱弧菌DbfRS双组分系统的直接调控机制。研究通过遗传学、蛋白互作及转录组分析，阐明DbfQ在调节DbfS的酶活性与生物膜分散中的关键作用。结果显示，DbfR磷酸化引发广泛转录调控，影响代谢与应激通路，其失调显著降低感染适应性。该研究不仅提出了DbfQ作为新型双组分系统调节子的新概念，也为开发针对细菌信号系统的抗感染策略提供了潜在靶点。整体而言，工作具有较高创新性，但后续仍需阐明DbfQ调控的分子结构基础及跨物种保守性。

---

## 26. 缺失半胱天冬酶8引导类神经祖细胞样重编程并促进小细胞肺癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413044)
**期刊：** Nature communications
**PMID：** 41413044
**DOI：** 10.1038/s41467-025-67142-4

### 第一部分 原文与翻译

**英文原标题：** Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression.

> **英文摘要：**
> Most neuroendocrine cancers lack caspase 8 protein expression. While this feature was thought to facilitate escape from extrinsic apoptosis, its cancer-regulatory function has remained unexplored. Here, we devise a mouse model of small cell lung cancer (SCLC) recapitulating the lack of expression of caspase 8 seen in humans and uncover an unexpected role for necroptosis-fueled pre-tumoral inflammation resulting in reprogramming towards a neuronal progenitor cell-like state and increased metastatic disease. Notably, transcriptional signatures of this cellular state are enriched in relapsed and metastatic human SCLC. Mechanistically, caspase 8 loss within the pre-tumoral niche promotes inflammation marked by increased recruitment of regulatory T cells (Tregs) which are responsible for the promotion of metastatic disease. Importantly, inactivation of the necroptosis executioner MLKL reverses pre-tumoral inflammation, decreases metastasis as well as neuronal-like reprogramming. Taken together, our findings suggest that pre-tumoral inflammatory cell death contributes to neuronal progenitor mimicry, immunosuppression and increased metastasis in SCLC.

> **中文摘要：**
> 大多数神经内分泌肿瘤缺乏半胱天冬酶8蛋白的表达。虽然这种特征被认为有助于逃避外源性凋亡，但其在癌症中的调控功能仍未被深入探讨。在本研究中，我们建立了一种小细胞肺癌（SCLC）小鼠模型，重现了人类中观察到的半胱天冬酶8缺失现象，并揭示了坏死性凋亡驱动的肿瘤前炎症的意外作用，该炎症导致了向类神经祖细胞状态的重编程，并促进了转移性疾病的增加。值得注意的是，这种细胞状态的转录特征在复发和转移性人类SCLC中显著富集。从机制上看，肿瘤前生态位中半胱天冬酶8的缺失会促进炎症，其特征为调节性T细胞（Tregs）的募集增加，而这些细胞在促进转移性疾病中起关键作用。重要的是，灭活坏死性凋亡效应分子MLKL可逆转肿瘤前炎症，减少转移以及类神经样重编程。综合来看，我们的研究结果表明，肿瘤前期的炎症性细胞死亡促进了神经祖细胞拟态、免疫抑制以及SCLC的转移增强。

### 第二部分 AI 大师评价

本研究利用小鼠模型揭示了半胱天冬酶8缺失在小细胞肺癌中除逃避凋亡外的关键致癌作用。研究发现，坏死性凋亡诱导的炎症可促使细胞向神经祖细胞样状态重编程，并伴随转移性增强。通过抑制坏死性凋亡执行因子MLKL可显著逆转上述过程。这一发现从炎症-细胞重编程-免疫逃逸的角度，拓展了对SCLC发生与进展机制的理解，具有潜在的治疗启示，但仍需临床验证其可转化性。

---

## 27. 局部治疗平台通过消除胶质母细胞瘤起始细胞并重塑免疫抑制性微环境以预防术后复发。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413041)
**期刊：** Nature communications
**PMID：** 41413041
**DOI：** 10.1038/s41467-025-67415-y

### 第一部分 原文与翻译

**英文原标题：** Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment.

> **英文摘要：**
> Glioblastoma multiforme (GBM) is characterized by aggressive invasiveness and poor prognosis, and presents a significant clinical challenge due to incomplete surgical resection, poor blood‒brain barrier penetration of therapeutic agents, and inevitable recurrence mainly driven by residual glioma-initiating cells (GICs) and an immunosuppressive microenvironment. Therefore, there is an urgent need to kill remaining GICs and reverse the immunosuppressive tumor microenvironment to prevent postoperative recurrence of GBM. Here, we design an injectable therapeutic platform that targets and kills remaining GICs and reverses the immunosuppressive microenvironment after postoperative resection to prevent the recurrence of GBM. This platform comprises GIC-targeting exosomes that carry siRNA for Notch1 and mitoxantrone to reduce the stemness of GICs and kill residual GICs and glioma cells, respectively, and an immune activator (interleukin-12), which can remodel the immunosuppressive tumor microenvironment, ultimately suppressing postoperative GBM relapse. Our work provides a perspective into the effective inhibition of postresection recurrence of GBM.

> **中文摘要：**
> 多形性胶质母细胞瘤（GBM）具有高度侵袭性和预后不良的特征，由于手术切除不完全、治疗药物穿透血脑屏障能力差以及不可避免的复发（主要由残余的胶质瘤起始细胞（GICs）和免疫抑制性微环境驱动）而构成显著的临床挑战。因此，迫切需要清除残留的GICs并逆转免疫抑制性肿瘤微环境，以防止GBM术后复发。在本研究中，我们设计了一种可注射的治疗平台，能够在术后针对并清除残余的GICs，同时逆转免疫抑制性微环境，从而预防GBM复发。该平台由靶向GIC的外泌体组成，这些外泌体携带Notch1的siRNA和米托蒽醌，分别用于降低GIC的干性并杀伤残留的GIC和胶质瘤细胞；此外还包含一种免疫激活因子（白介素-12），它能够重塑免疫抑制性肿瘤微环境，最终抑制术后GBM的复发。我们的研究为有效抑制GBM术后复发提供了一种新的视角。

### 第二部分 AI 大师评价

本文旨在开发一种可注射的局部治疗平台，以同时消除胶质瘤起始细胞并重塑免疫微环境，预防胶质母细胞瘤术后复发。研究通过GIC靶向外泌体、siRNA敲降Notch1以及米托蒽醌的联合应用，兼顾了细胞杀伤与GIC干性抑制，同时利用白介素-12增强免疫活性。该策略创新性地融合了分子干预与免疫调控，展示出在GBM复发防治中的显著潜力。尽管疗效显著，但其在临床转化中的安全性、可控性及递送系统稳定性仍需进一步验证。

---

## 28. 立体定向体部放疗联合信迪利单抗及贝伐珠单抗生物类似药治疗抗PD-1耐药性肝细胞癌：ReUNION-1 二期临床试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413036)
**期刊：** Nature communications
**PMID：** 41413036
**DOI：** 10.1038/s41467-025-67528-4

### 第一部分 原文与翻译

**英文原标题：** Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial.

> **英文摘要：**
> Immune checkpoint inhibitor (ICI) resistance in hepatocellular carcinoma (HCC) poses a major therapeutic challenge. Here we present a Phase 2 trial evaluating stereotactic body radiotherapy (SBRT) combined with sintilimab and bevacizumab biosimilar (PD-1/VEGF blockade) to overcome resistance in ICI-refractory HCC. Twenty-one patients with progressive HCC after ICI therapy receive SBRT followed by sintilimab 200 mg and bevacizumab biosimilar 15 mg/kg every 3 weeks. The primary outcome, objective response rate in non-irradiated lesions is 33.3%, with a disease control rate of 66.7%. Median progression-free survival is 6.2 months, and estimated median overall survival is 24.4 months. SBRT achieves 100% local control, with 33.3% experiencing grade 3 or higher adverse events. Proteomic profiling reveals that responders exhibit lower baseline IFN-γ and elevated IL-6, while post-SBRT increases in IFN-γ, IL-2, and IL-6 correlate with improved outcomes. These results indicate that combination of SBRT in ICI-refractory HCC is effective, well-tolerated, and may be guided by cytokine assessment.

> **中文摘要：**
> 肝细胞癌（HCC）对免疫检查点抑制剂（ICI）的耐药性构成主要治疗挑战。本研究报道了一项二期临床试验，评估立体定向体部放疗（SBRT）联合信迪利单抗和贝伐珠单抗生物类似药（PD-1/VEGF 双重阻断）在ICI耐药性HCC患者中克服耐药的疗效。共有21例在接受ICI治疗后进展的HCC患者接受了SBRT治疗，随后每3周给予信迪利单抗200 mg及贝伐珠单抗生物类似药15 mg/kg。主要终点为非照射病灶的客观缓解率，为33.3%，疾病控制率为66.7%。中位无进展生存期为6.2个月，估算的中位总生存期为24.4个月。SBRT实现了100%的局部控制率，33.3%的患者发生3级或以上不良事件。蛋白质组学分析显示，治疗应答者在基线时具有较低的IFN-γ水平和较高的IL-6水平，而SBRT后IFN-γ、IL-2和IL-6的升高与更好的临床结局相关。这些结果表明，SBRT联合治疗在ICI耐药性HCC患者中具有良好疗效和耐受性，并可通过细胞因子评估进行个体化指导。

### 第二部分 AI 大师评价

该研究旨在探索通过立体定向体部放疗联合免疫与抗血管治疗克服肝细胞癌对PD-1抑制剂的耐药性。结果显示，该联合方案在既往失败于ICI治疗的患者中具有较高的客观缓解率和持久的生存获益，并表现出可接受的安全性。蛋白质组学揭示了细胞因子变化与疗效之间的相关性，为耐药机制与治疗反应提供了生物标志物线索。该研究创新性地将放疗与双重阻断策略相结合，但仍受样本量较小及单臂设计的局限。

---

## 29. H2AK119ub动态调控毛囊干细胞的静息状态

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413035)
**期刊：** Nature communications
**PMID：** 41413035
**DOI：** 10.1038/s41467-025-66471-8

### 第一部分 原文与翻译

**英文原标题：** H2AK119ub dynamics control hair follicle stem cell quiescence.

> **英文摘要：**
> Adult stem cells (SCs) transition between quiescent and active states to maintain tissue integrity, and dysregulation of this balance can lead to tissue degeneration, cancer, or premature aging. Both intrinsic factors and extrinsic niche signals influence these states; however, the molecular mechanisms that integrate extrinsic cues with intrinsic programs remain poorly understood. Here, we show that the conserved repressive histone mark, H2AK119ub, serves as a molecular switch linking inhibitory fibroblast growth factor (FGF) signals with the quiescent transcriptional program in hair follicle stem cells (HFSCs). Modulation of FGF signaling is associated with changes in H2AK119ub levels, thereby toggling HFSCs between quiescence and activation states. Mechanistically, H2AK119ub directly represses a proliferation-promoting transcriptional program preserving HFSC quiescence. Loss of H2AK119ub in HFSCs shortens the quiescent phase and induces repeated rounds of HFSC activation, ultimately leading to SC exhaustion - a hallmark of aging tissue. Analysis of other mammalian SC systems and Drosophila germline SCs confirms that H2AK119ub is a broadly conserved hallmark of quiescence and is dynamic upon SC activation. These findings reveal a signaling-epigenetic axis that controls SC quiescence and underscores the importance of the conserved role of H2AK119ub in maintaining tissue homeostasis.

> **中文摘要：**
> 成体干细胞（SCs）在静息与活化状态之间转变以维持组织完整性，而这种平衡的失调可能导致组织退化、癌症或早衰。内在因素与外源性微环境信号共同影响这些状态；然而，将外源性信号与内在程序整合的分子机制仍知之甚少。在此研究中，我们发现保守的组蛋白抑制性修饰标记H2AK119ub，作为分子开关，将抑制性的成纤维生长因子（FGF）信号与毛囊干细胞（HFSCs）的静息转录程序相连。FGF信号调节伴随H2AK119ub水平变化，从而在HFSCs的静息与活化状态之间切换。从机制上看，H2AK119ub直接抑制促进细胞增殖的转录程序，从而维持HFSCs的静息状态。当HFSCs失去H2AK119ub时，其静息阶段缩短并引发连续多轮活化，最终导致干细胞耗竭，这是衰老组织的特征之一。对其他哺乳动物干细胞系统及果蝇生殖系干细胞的分析证实，H2AK119ub是静息状态的广泛保守标志，并在干细胞活化时表现出动态变化。这些发现揭示了一个信号-表观遗传轴，它控制干细胞的静息状态，并强调了H2AK119ub在维持组织稳态中的保守性关键作用。

### 第二部分 AI 大师评价

本研究揭示了H2AK119ub作为连接外源性FGF信号与内在静息转录程序的核心表观遗传调控机制，阐明其在毛囊干细胞静息与活化切换中的关键作用。研究通过多系统验证其保守性，说明H2AK119ub是干细胞静息的普适分子标志。结果不仅为理解干细胞动态平衡提供了重要机制依据，也为防止组织老化与干细胞耗竭提供了潜在靶点。其创新性在于揭示了信号传导与表观遗传调控的关键交汇点，但具体调控网络的上下游组成尚待进一步解析。

---

## 30. 具备体积相变特性的纳米凝胶及其生物医学应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413033)
**期刊：** Nature communications
**PMID：** 41413033
**DOI：** 10.1038/s41467-025-67780-8

### 第一部分 原文与翻译

**英文原标题：** Nanogels with volume phase transition for biomedical applications.

> **英文摘要：**
> Nanogels, of which the three-dimensional network structures are covalently crosslinked by crosslinkers and supported by large number of hydrogen bonds, present unique volume phase transition (VPT) and play significant roles in multiple biomedical applications. Based on hydrogen bonds, the VPT features including the shift, sharpness, and range of VPT, can be rationally designed and precisely controlled by simply regulating the monomer, comonomer, crosslinker, structure, deuteration, environmental stimuli, and so on, for tailored biomedical applications such as transcatheter arterial embolization (TAE) and tumor targeting drug delivery (TTDD). Moreover, the exploration of the minimum value of physicochemical properties around volume phase transition temperature (VPTT) exhibits great potential in improving current tumor therapies and developing more therapeutic strategies. Integrating systematic knowledge of nanogel VPT properties, we provide the guidance for rational design of nanogels with tailored biomedical applications.

> **中文摘要：**
> 纳米凝胶的三维网络结构通过交联剂实现共价交联，并由大量氢键支撑，表现出独特的体积相变（VPT）特性，并在多种生物医学应用中发挥重要作用。基于氢键，体积相变的特征，包括相变的位移、锐度和范围，可通过对单体、共聚单体、交联剂、结构、氘代、环境刺激等因素的简单调控，进行合理设计与精确控制，以实现针对性生物医学应用，如经导管动脉栓塞（TAE）和肿瘤靶向药物递送（TTDD）。此外，对体积相变温度（VPTT）附近物理化学性质的最小值进行探索，在改善当前肿瘤治疗和开发更多治疗策略方面展示出巨大潜力。通过整合纳米凝胶体积相变特性的系统知识，本文为合理设计具有特定生物医学应用功能的纳米凝胶提供了指导。

### 第二部分 AI 大师评价

该研究系统总结了纳米凝胶体积相变特性的调控机制，并提出通过分子结构和环境因素精确控制相变行为的策略。作者强调氢键在决定相变特征中的关键作用，并将其与具体的生物医学应用如动脉栓塞与肿瘤药物递送相结合，体现了高度的可设计性和临床转化潜力。研究创新性在于将相变热力学特征与功能设计相融合，为纳米材料定向调控提供了新思路。然而，对于实际生理环境下的动态响应与安全性仍需进一步实验验证。

---

## 31. RPL5缺失引发的核糖体应激靶向特定蛋白亚群并抑制PI3K-Akt-mTOR信号通路以清除白血病干细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413025)
**期刊：** Cell death & disease
**PMID：** 41413025
**DOI：** 10.1038/s41419-025-08379-1

### 第一部分 原文与翻译

**英文原标题：** RPL5 deficiency-induced ribosomal stress targets a select subset of proteins and inhibits the PI3K-Akt-mTOR signaling pathway to eradicate leukemia stem cells.

> **英文摘要：**
> Ribosomal protein L5 (RPL5) is considered a haplo-insufficient tumor suppressor by upregulating p53 expression or promoting the inactivation of c-Myc in solid tumors upon tumor initiation. However, its detailed effect and mechanism in tumor maintenance were more complicated. Particularly, the specific role of RPL5 in acute myeloid leukemia (AML) remains unclear. In this study, we found that RPL5 expression was increased in primary AML blasts compared with normal controls, regardless of TP53 mutation. RPL5 knockdown reduced the survival and colony-forming ability of AML cells in vitro, as well as inhibited the engraftment of leukemia stem cells (LSCs) in vivo. It indicated that RPL5 was required for the survival of AML cells, especially for maintaining the stemness of LSCs. The data analysis of RNA-seq and proteomics revealed that RPL5 deficiency eradicated LSC by inducing a cellular stress response, i.e., ribosomal stress, rather than a specific function relating to RPL5. The inhibited PI3K-Akt-mTOR signaling pathway played a central role in the ribosomal stress induced by RPL5 deficiency. To investigate the selectivity of RPL5 depletion in eradicating LSCs, we found that RPL5 expression was highest in LSCs compared to AML cells and healthy controls. Moreover, ribosomal stress specifically affected transcripts with longer exon lengths and proteins with a lower isoleucine (Ile) to valine (Val) ratio. Ile and Val are glycogenic branched-chain amino acids (BCAAs) that regulate fundamental cell processes by affecting mTOR activation through BCAA metabolism. In conclusion, RPL5 depletion-induced ribosomal stress disrupted stemness maintenance by affecting BCAA metabolism in AML, specifically inhibiting the PI3K-Akt-mTOR signaling pathway, which resulted in LSC eradication.

> **中文摘要：**
> 核糖体蛋白L5（RPL5）被认为是一种半量缺失型肿瘤抑制因子，可在实体瘤发生过程中通过上调p53表达或促进c-Myc失活发挥作用。然而，它在肿瘤维持中的具体作用及机制更为复杂。尤其是，RPL5在急性髓系白血病（AML）中的特定作用仍不清楚。本研究发现，与正常对照相比，原发性AML原始细胞中RPL5表达升高，且与TP53突变无关。RPL5的敲低在体外降低了AML细胞的存活率和集落形成能力，并在体内抑制了白血病干细胞（LSCs）的植入。这表明RPL5对于AML细胞的生存必不可少，尤其在维持LSC干性方面起关键作用。RNA测序和蛋白质组学数据分析显示，RPL5缺失通过诱导细胞应激反应，即核糖体应激，而非与RPL5的特定功能相关的机制，来消除LSC。被抑制的PI3K-Akt-mTOR信号通路在RPL5缺失诱发的核糖体应激中起核心作用。为研究RPL5缺失清除LSC的选择性，我们发现RPL5在LSC中的表达最高，高于AML细胞及健康对照。此外，核糖体应激特异性影响外显子长度较长的转录本及异亮氨酸（Ile）与缬氨酸（Val）比例较低的蛋白。Ile和Val是糖原生支链氨基酸（BCAA），可通过BCAA代谢影响mTOR活化，从而调节基本的细胞过程。综上所述，RPL5缺失诱导的核糖体应激通过影响AML中的BCAA代谢，特异性抑制PI3K-Akt-mTOR信号通路，进而破坏干性维持并清除LSC。

### 第二部分 AI 大师评价

该研究聚焦于核糖体蛋白RPL5在急性髓系白血病中的功能，揭示其在维持白血病干细胞生存与干性方面的关键作用。研究通过RNA测序与蛋白质组学相结合，发现RPL5缺失导致核糖体应激并抑制PI3K-Akt-mTOR信号通路，从而选择性清除LSC。其创新之处在于将RPL5与支链氨基酸代谢联系起来，提示代谢调控可成为AML干细胞靶向的新途径。研究虽主要基于细胞与小鼠模型，但为靶向核糖体应激通路治疗AML提供了新的思路。

---

## 32. 锰改造乳酸杆菌Reuteri在结直肠癌预防与治疗中具有增强的抗肿瘤和免疫调节活性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413024)
**期刊：** Nature communications
**PMID：** 41413024
**DOI：** 10.1038/s41467-025-67437-6

### 第一部分 原文与翻译

**英文原标题：** Manganese-engineered Lactobacillus Reuteri with enhanced antitumor and immunomodulatory activities for colorectal cancer prevention and treatment.

> **英文摘要：**
> Probiotic-based biotherapy for colorectal cancer (CRC) faces significant challenges due to poor tumor-targeting and limited bioactivities within the complex tumor microenvironment. This study shows that Lactobacillus reuteri (L. reuteri)'s inherent bioactivities, including proliferation, metabolism, and colorectal colonization, can be enhanced by manganese, prompting the fabrication of a manganese-engineered strain (MnLR). Oral administration of MnLR with its metabolic substrate-glycerol (MnLR/Gly) promotes the enrichment of L. reuteri and its antitumor metabolites within colon tumors. Across multiple preclinical colon tumor models, MnLR/Gly alone achieves a 95.6% inhibition of orthotopic tumor growth, liver metastases reduction by 62.1%, and confers durable protection, with 75% of prophylactically treated mice remaining long-term tumor-free and 62.5% resisting tumor rechallenge. Mechanistically, MnLR/Gly induces both intratumoral and peripheral dendritic cell maturation, M1 macrophage polarization, and effector T-cell responses. In orthotopic CRC rabbit models, GlyMnLR enteric capsules demonstrate significant antitumor efficacy comparable to standard chemotherapy while exhibiting favorable safety. These findings highlight MnLR as an effective standalone probiotic therapy for CRC prevention and treatment.

> **中文摘要：**
> 基于益生菌的结直肠癌（CRC）生物疗法因肿瘤靶向性差及在复杂肿瘤微环境中生物活性有限而面临重大挑战。本研究表明，乳酸杆菌Reuteri（L. reuteri）固有的生物活性，包括增殖、代谢及结直肠定殖能力，可通过锰元素增强，从而构建出一种锰改造菌株（MnLR）。口服MnLR及其代谢底物甘油（MnLR/Gly）可促进L. reuteri及其抗肿瘤代谢物在结肠肿瘤中的富集。在多种结肠肿瘤的临床前模型中，单独使用MnLR/Gly即可实现95.6%的原位肿瘤生长抑制率，肝转移减少62.1%，并赋予持久保护作用，其中75%的预防性处理小鼠长期无瘤生存，且62.5%的小鼠对肿瘤再挑战具有抵抗性。从机制上看，MnLR/Gly可诱导肿瘤内及外周树突状细胞成熟、M1型巨噬细胞极化及效应性T细胞反应。在结直肠癌兔原位模型中，GlyMnLR肠溶胶囊显示出与标准化疗相当的显著抗肿瘤效应，且安全性良好。这些发现突显MnLR作为一种有效的独立益生菌疗法在结直肠癌预防与治疗中的潜力。

### 第二部分 AI 大师评价

该研究旨在通过金属元素调控策略，增强乳酸杆菌Reuteri的抗肿瘤与免疫调节功能，以应对结直肠癌益生菌治疗中存在的肿瘤靶向性及活性不足问题。研究采用锰改造菌株并结合甘油代谢底物，通过多种动物模型验证其抑瘤、抗转移及免疫激活效应。结果显示，MnLR/Gly具有显著的抗肿瘤效力和良好安全性。创新之处在于将金属元素工程化与益生菌疗法相结合，为结直肠癌防治提供了新思路。局限性可能在于临床转化的复杂性及长期安全性仍待进一步验证。

---

## 33. 靶向SMAD3/CISD2轴通过促进间质样膀胱癌细胞铁死亡抑制膀胱癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413023)
**期刊：** Cell death & disease
**PMID：** 41413023
**DOI：** 10.1038/s41419-025-08339-9

### 第一部分 原文与翻译

**英文原标题：** Targeting the SMAD3/CISD2 axis suppresses bladder cancer progression by promoting ferroptosis in mesenchymal-like bladder cancer cells.

> **英文摘要：**
> The poor prognosis of bladder cancer (BCa) is primarily attributed to the acquisition of invasive and metastatic capabilities by tumor cells through epithelial-mesenchymal transition (EMT), yet the dynamic alterations in ferroptosis during EMT and their regulatory mechanisms remain unelucidated. This study is the first to reveal the mechanism by which the Smad3/CISD2 signaling axis regulates ferroptosis in mesenchymal-like bladder cancer cells. Clinical sample analysis demonstrated significantly reduced expression of E-cadherin and upregulation of N-cadherin and Vimentin in muscle-invasive bladder cancer tissues (MIBC), with EMT-related marker levels correlating with overall survival rates in BCa patients. In TGF-β1-induced mesenchymal-like bladder cancer cells, ferroptosis-related genes (GPX4, SLC7A11) were markedly elevated, alongside increased lipid peroxides (LPO) and glutathione (GSH) levels. However, mesenchymal-like bladder cancer cells exhibited heightened sensitivity to the ferroptosis inducer Erastin, showing more pronounced suppression of proliferation, elevated ROS, higher LPO and MDA levels, and reduced GSH, confirming their enhanced susceptibility to ferroptosis. RNA-seq revealed significant downregulation of Smad3 in ferroptosis inducer treated mesenchymal-like bladder cancer cells. Smad3 knockdown further exacerbated ferroptosis markers (elevated Fe²⁺, ROS, LPO; decreased GSH), inhibited migration, invasion, and proliferation-phenotypes reversible by ferroptosis inhibitors. Mechanistically, ChIP-seq combined with RNA-seq demonstrated that Smad3 regulates CISD2 expression by binding its promoter region, with clinical specimens confirming a positive correlation between Smad3 and CISD2 expression. Functional rescue experiments showed that CISD2 overexpression in Smad3-knockdown mesenchymal-like bladder cancer cells reversed abnormal increases in Fe²⁺, ROS, LPO, and MDA while restoring GSH levels, indicating that Smad3 modulates ferroptosis through a CISD2-dependent pathway. In vivo experiments further demonstrated that targeting the Smad3/CISD2 axis significantly suppressed xenograft tumor growth and activated ferroptosis. In conclusion, this study elucidates a novel mechanism by which the Smad3/CISD2 axis dynamically regulates ferroptosis through redox homeostasis reprogramming during EMT, providing a potential therapeutic strategy for targeting the progression of MIBC.

> **中文摘要：**
> 膀胱癌（BCa）预后不良主要归因于肿瘤细胞通过上皮-间质转化（EMT）获得侵袭性和转移能力，但EMT过程中铁死亡的动态变化及其调控机制尚不清楚。本研究首次揭示了Smad3/CISD2信号轴在间质样膀胱癌细胞中调控铁死亡的机制。临床样本分析显示，肌层浸润性膀胱癌组织（MIBC）中E-cadherin表达显著下降，而N-cadherin和Vimentin表达上调，EMT相关标志物水平与BCa患者的总体生存率相关。在TGF-β1诱导的间质样膀胱癌细胞中，铁死亡相关基因（GPX4、SLC7A11）显著升高，同时脂质过氧化物（LPO）和谷胱甘肽（GSH）水平增加。然而，间质样膀胱癌细胞对铁死亡诱导剂Erastin表现出更高的敏感性，其增殖受到更强抑制，ROS水平升高，LPO和MDA水平更高，GSH水平降低，证实其对铁死亡的易感性增强。RNA测序结果显示，铁死亡诱导剂处理的间质样膀胱癌细胞中Smad3显著下调。敲低Smad3进一步加剧了铁死亡标志（Fe²⁺、ROS、LPO升高；GSH下降），抑制了迁移、侵袭和增殖，而这些表型可被铁死亡抑制剂逆转。在机制上，ChIP-seq与RNA-seq联合显示，Smad3通过结合CISD2启动子区域调控其表达，临床样本亦证实Smad3与CISD2表达呈正相关。功能性救援实验表明，在Smad3敲低的间质样膀胱癌细胞中过表达CISD2可逆转Fe²⁺、ROS、LPO和MDA的异常升高并恢复GSH水平，提示Smad3通过CISD2依赖性途径调控铁死亡。体内实验进一步证实，靶向Smad3/CISD2轴显著抑制异种移植瘤生长并激活铁死亡。综上所述，本研究阐明了Smad3/CISD2轴通过氧化还原稳态重编程在EMT过程中动态调控铁死亡的新机制，为靶向MIBC进展提供了潜在治疗策略。

### 第二部分 AI 大师评价

本研究揭示了Smad3/CISD2信号轴在调控间质样膀胱癌细胞铁死亡中的关键作用，阐明了肿瘤EMT过程中铁死亡调控的动态机制。研究通过临床样本、体外分子实验以及体内肿瘤模型系统性验证了Smad3/CISD2通路在维持氧化还原稳态中的功能。发现靶向该轴可通过促进铁死亡抑制膀胱癌进展，显示出重要的治疗潜力。其创新性在于首次关联Smad3介导的信号调控与铁死亡敏感性，但仍需进一步研究其在不同分子亚型中的普适性与临床转化可行性。

---

## 34. 基于多队列析出的外源实验大鼠宿主-微生物组相互作用的遗传结构与机制研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413022)
**期刊：** Nature communications
**PMID：** 41413022
**DOI：** 10.1038/s41467-025-66105-z

### 第一部分 原文与翻译

**英文原标题：** Genetic architecture and mechanisms of host-microbiome interactions from a multi-cohort analysis of outbred laboratory rats.

> **英文摘要：**
> The intestinal microbiome influences health and disease. Its composition is affected by host genetics and environmental exposures. Understanding host genetic effects is critical but challenging in humans, due to the difficulty of detecting, mapping and interpreting them. To address this, we analyse host genetic effects in four cohorts of outbred laboratory rats exposed to distinct but controlled environments. We show that polygenic host genetic effects are consistent across cohort environments. We identify three replicated microbiome-associated loci, one of which involves the sialyltransferase gene St6galnac1 and Paraprevotella. We find a similar association in a human cohort, between ST6GAL1 and Paraprevotella, both of which have been linked with immune and infectious diseases. Moreover, we find indirect (i.e. social) genetic effects on microbiome phenotypes, which substantially increase the total genetic variance. Finally, we identify a novel mechanism whereby indirect genetic effects can contribute to "missing heritability".

> **中文摘要：**
> 肠道微生物群影响健康与疾病。其组成受宿主遗传因素和环境暴露的影响。由于检测、定位和解释这些影响的难度，在人类中理解宿主遗传效应至关重要但极具挑战。为此，我们分析了四个分别暴露于不同但受控环境中的外源实验大鼠队列的宿主遗传效应。结果显示，多基因宿主遗传效应在不同队列环境间保持一致。我们鉴定出三个可重复的与微生物组相关的基因座，其中一个涉及唾液酸转移酶基因St6galnac1与Paraprevotella属。我们在一个人类队列中发现了类似关联，即ST6GAL1与Paraprevotella之间的关系，这两者均与免疫和感染性疾病有关。此外，我们发现了对微生物组表型的间接（即社会性）遗传效应，这显著增加了总遗传方差。最后，我们发现一种新的机制，即间接遗传效应可能对“缺失的遗传力”有所贡献。

### 第二部分 AI 大师评价

本研究旨在解析宿主遗传因素对肠道微生物群的影响机制，采用跨四个外源实验大鼠队列的多队列遗传分析。研究发现宿主多基因效应在不同环境中具有一致性，并鉴定出三个可重复的微生物组相关位点，同时在人群样本中验证了ST6GAL1与Paraprevotella的跨物种关联。研究还揭示了间接遗传效应可显著增加微生物组性状的遗传方差，并提出其可能部分解释“缺失遗传力”问题。该工作给出了宿主—微生物互作遗传机制的新视角，但未来仍需在不同物种及自然人群中进一步验证其普适性。

---

## 35. ACSS1劫持乙酰辅酶A代谢以促进DNA修复并削弱乳腺癌放疗疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413018)
**期刊：** Cell death & disease
**PMID：** 41413018
**DOI：** 10.1038/s41419-025-08300-w

### 第一部分 原文与翻译

**英文原标题：** ACSS1 co-opts acetyl-CoA metabolism to drive DNA repair and undermine radiotherapy efficacy in breast cancer.

> **英文摘要：**
> Breast cancer remains a leading cause of cancer-related mortality worldwide, with radiotherapy serving as a cornerstone of treatment. However, the development of radioresistance significantly compromises therapeutic efficacy and patient outcomes. Through integrative analysis of TCGA and GEO datasets combined with quantitative proteomics, we identified acetyl-CoA synthetase 1 (ACSS1) as a key driver of radioresistance in breast cancer. ACSS1 is aberrantly overexpressed in breast cancer and correlates with poor prognosis following radiotherapy. Functional studies revealed that overexpressed ACSS1 is able to enhance radioresistance both in vitro and in vivo. Mechanistically, ACSS1 amplifies the ionizing radiation (IR)-induced metabolic coupling of pyruvate with ROS for acetate synthesis, which fuels energy production and expands the nuclear acetyl-CoA pool, enabling histone acetylation at DNA damage sites. Such acetylation promotes chromatin relaxation at damage sites, facilitating the recruitment of homologous recombination (HR) repair machinery and ultimately leading to radioresistance. Our findings reveal that ACSS1 orchestrates acetyl-CoA-driven histone acetylation to enhance DNA repair efficiency, highlighting a metabolic-epigenetic crosstalk that sustains radioresistance in breast cancer. Targeting ACSS1 represents a promising therapeutic strategy to sensitize tumours to radiotherapy and improve clinical outcomes in breast cancer patients.

> **中文摘要：**
> 乳腺癌仍然是全球癌症相关死亡的主要原因之一，而放射治疗是治疗的基石。然而，放射抗性的发展显著削弱了治疗效果并影响患者预后。通过整合TCGA和GEO数据库分析并结合定量蛋白质组学，我们鉴定出乙酰辅酶A合成酶1（ACSS1）是乳腺癌放射抗性的关键驱动因子。ACSS1在乳腺癌中异常高表达，并与放疗后的不良预后相关。功能研究表明，ACSS1的过度表达可在体外和体内增强放射抗性。机制上，ACSS1放大了电离辐射（IR）诱导的丙酮酸与活性氧（ROS）的代谢偶联以合成乙酸，从而促进能量生成并扩大神经核内乙酰辅酶A库，进而介导DNA损伤位点的组蛋白乙酰化。这种乙酰化促进了损伤位点的染色质松弛，有利于同源重组（HR）修复机制的招募，最终导致放射抗性。我们的研究结果揭示了ACSS1通过乙酰辅酶A驱动的组蛋白乙酰化来增强DNA修复效率，强调了维持乳腺癌放射抗性的代谢-表观遗传学互作。靶向ACSS1代表一种有前景的治疗策略，可使肿瘤对放疗敏感化并改善乳腺癌患者的临床结局。

### 第二部分 AI 大师评价

该研究聚焦于乳腺癌放射抗性的代谢学与表观遗传学机制，系统整合了多组学数据与功能实验证据。研究明确了ACSS1通过调控乙酰辅酶A代谢及组蛋白乙酰化，促进DNA修复和染色质松弛，从而驱动放疗抗性。该机制揭示了肿瘤代谢与DNA修复之间的关键联系，具有显著的创新性。尽管实验设计全面，但临床层面的验证仍需进一步加强。靶向ACSS1可能成为提升放疗敏感性的新型癌症治疗策略。

---

## 36. 由 NSUN 驱动的失调：靶向癌症治疗的下一个前沿？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413017)
**期刊：** Cell death & disease
**PMID：** 41413017
**DOI：** 10.1038/s41419-025-08269-6

### 第一部分 原文与翻译

**英文原标题：** NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?

> **英文摘要：**
> Epitranscriptomic modifications represent a fundamental regulatory layer in cancer biology, with RNA methylation emerging as a pivotal mechanism governing transcriptomic dynamics. Among these, 5-methylcytosine (mC) RNA methylation-a ubiquitous and conserved epitranscriptomic mark-has been identified across diverse RNA species, including mRNAs, rRNAs, tRNAs, and mitochondrial RNAs. Notably, the RNA mC "writers"-enzymes responsible for installing this modification onto target RNAs-have emerged as central regulators of tumorigenesis, with NSUN (NOP2/Sun RNA methyltransferase) proteins playing a particularly pivotal role. We synthesize current knowledge of the cellular localization, substrate specificity, and biological functions of mC-modifying enzymes, focusing predominantly on the NSUN family in the cancer context. We first dissect the spatiotemporal regulation patterns of NSUN proteins-from their nuclear roles in pre-mRNA processing to cytoplasmic functions in mRNA decay and translation-and their conserved methyltransferase domains that dictate target RNA recognition. This review further explores the molecular mechanisms by which NSUN proteins govern tumor progression, metastasis, and therapeutic responses, emphasizing their dual roles in both initiating oncogenic programs and maintaining cancer cell plasticity. Finally, we discuss the translational implications of targeting NSUN-mediated mC pathways, highlighting small-molecule inhibitors designed against NSUN substrate specificity, combinatorial strategies with conventional chemotherapy or immunotherapy, and the promise of epitranscriptomic diagnostics and prognostic based on NSUN expression signatures. By positioning NSUN proteins as integral nodes in the RNA epigenomic network, this synthesis not only deepens our understanding of cancer pathogenesis but also identifies novel epitranscriptomic targets for precision oncology.

> **中文摘要：**
> 表观转录组修饰代表了癌症生物学中的一个基础调控层，其中 RNA 甲基化正在成为支配转录组动态变化的关键机制。在这些修饰中，5-甲基胞嘧啶（mC）RNA 甲基化——一种普遍存在且保守的表观转录组标记——已在包括 mRNA、rRNA、tRNA 和线粒体 RNA 在内的多种 RNA 类型中被鉴定。值得注意的是，负责将此修饰加到靶 RNA 上的 RNA mC “书写酶”已被确认为肿瘤发生的核心调控因子，其中 NSUN（NOP2/Sun RNA 甲基转移酶）蛋白发挥着尤其关键的作用。我们综合了关于 mC 修饰酶的细胞定位、底物特异性及生物学功能的现有知识，重点聚焦于癌症背景下的 NSUN 家族。我们首先剖析了 NSUN 蛋白的时空调控模式——从其在细胞核中参与前体 mRNA 加工的功能，到在细胞质中调控 mRNA 降解与翻译的作用——以及决定靶 RNA 识别的保守甲基转移酶结构域。本综述进一步探讨了 NSUN 蛋白在调控肿瘤进展、转移及治疗反应中的分子机制，突出其在启动致癌程序与维持癌细胞可塑性中的双重作用。最后，我们讨论了靶向 NSUN 介导的 mC 通路的转化意义，重点介绍了针对 NSUN 底物特异性设计的小分子抑制剂、与常规化疗或免疫治疗相结合的联合策略，以及基于 NSUN 表达特征的表观转录组诊断与预后潜力。通过将 NSUN 蛋白定位为 RNA 表观基因组网络中的关键节点，本综述不仅深化了我们对癌症发病机制的理解，也为精准肿瘤学识别了新的表观转录组靶点。

### 第二部分 AI 大师评价

该综述旨在系统阐述 NSUN 家族甲基转移酶在癌症中介导的 RNA 5-甲基胞嘧啶修饰的生物学作用。作者整合了 NSUN 蛋白的结构特征、时空分布及其在转录后调控、肿瘤进展与治疗反应中的作用机制。文章的创新性在于将 NSUN 视为表观转录组网络的核心节点，并提出其作为潜在药物靶点的可行性。该研究为精准肿瘤治疗提供了新的思路，但仍需更多实验验证其临床转化潜力。

---

## 37. 新型 CDK2/4/6 抑制剂 culmerciclib（TQB3616）联合氟维司群用于经治 HR 阳性、HER2 阴性晚期乳腺癌的随机、双盲、Ⅲ 期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413016)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41413016
**DOI：** 10.1038/s41392-025-02475-6

### 第一部分 原文与翻译

**英文原标题：** Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial.

> **英文摘要：**
> CDK2 is a principal mediator of CDK4/6 resistance. Concurrent CDK2/4/6 blockade may be effective in treating HR-positive, HER2-negative advanced breast cancer (ABC). This randomized, double-blind, parallel-controlled, phase 3 trial (ClinicalTrials.gov, NCT05375461) assessed the efficacy of culmerciclib, a CDK2/4/6 inhibitor, plus fulvestrant in ABC. Patients with HR-positive, HER2-negative, locally recurrent or metastatic breast cancer were randomized (2:1) to receive culmerciclib plus fulvestrant or matching placebo plus fulvestrant. Between March 18, 2022 and March 3, 2023, 293 pretreated patients (median age 53.0 years; pre- or perimenopausal 42.3%; bone metastasis 65.2%) were randomized to assigned treatments. At this prespecified interim analysis, culmerciclib plus fulvestrant extended the median investigator-assessed progression-free survival (PFS) significantly, the primary endpoint, as compared with placebo plus fulvestrant (16.6 months, 95% CI 13.8 to not evaluable versus 7.5 months, 95% CI 5.3 to 11.0; hazard ratio 0.36, 95% CI 0.26-0.51; stratified log rank test P < 0.001). Consistent effects were observed across diverse subgroups of patients. At a median follow-up duration of 13.8 months, overall survival was immature. The investigators-assessed objective response rate was 40.2% (95% CI, 33.3-47.5) for culmerciclib compared to 12.1% (95% CI 6.4-20.2) for placebo (stratified Mantel-Haenszel χ test P < 0.001). Diarrhea (87.1%) and neutropenia (80.4%) were the most common toxicities with culmerciclib plus fulvestrant. In conclusion, this randomized clinical trial met its primary outcome. Culmerciclib plus fulvestrant is well tolerated and leads to a significant gain in PFS of pretreated HR-positive HER2-negative ABC patients.

> **中文摘要：**
> CDK2 是 CDK4/6 耐药的主要介导因子。同步阻断 CDK2/4/6 可能对 HR 阳性、HER2 阴性晚期乳腺癌（ABC）的治疗有效。本随机、双盲、平行对照的Ⅲ期临床试验（ClinicalTrials.gov, NCT05375461）评估了 CDK2/4/6 抑制剂 culmerciclib 联合氟维司群在 ABC 中的疗效。纳入 HR 阳性、HER2 阴性且局部复发或转移性乳腺癌患者，按 2:1 比例随机分配接受 culmerciclib 联合氟维司群或匹配安慰剂联合氟维司群治疗。2022 年 3 月 18 日至 2023 年 3 月 3 日期间，共招募并随机分配了 293 名既往经治患者（中位年龄 53.0 岁；绝经前或围绝经期 42.3%；伴骨转移 65.2%）。在预先设定的期中分析中，与安慰剂联合氟维司群相比，culmerciclib 联合氟维司群显著延长了研究者评估的无进展生存期（PFS），这是研究的主要终点（16.6 个月，95% CI 13.8 至未评估，与 7.5 个月，95% CI 5.3–11.0 相比；风险比 0.36，95% CI 0.26–0.51；分层对数秩检验 P < 0.001）。在不同患者亚组中均观察到一致的疗效。在中位 13.8 个月的随访时，总生存数据尚不成熟。研究者评估的客观缓解率为 culmerciclib 组 40.2%（95% CI, 33.3–47.5），而安慰剂组为 12.1%（95% CI 6.4–20.2）（分层 Mantel-Haenszel χ 检验 P < 0.001）。腹泻（87.1%）和中性粒细胞减少（80.4%）是 culmerciclib 联合氟维司群最常见的不良反应。总之，本随机临床试验达到了主要终点。culmerciclib 联合氟维司群耐受性良好，并显著提高了经治 HR 阳性、HER2 阴性晚期乳腺癌患者的无进展生存期。

### 第二部分 AI 大师评价

该研究旨在验证新型 CDK2/4/6 抑制剂 culmerciclib 联合氟维司群用于经治 HR 阳性、HER2 阴性晚期乳腺癌的疗效与安全性。结果显示，联合治疗显著改善了患者的无进展生存期和客观缓解率，同时整体耐受性良好。研究设计为随机、双盲、对照的Ⅲ期试验，方法学严谨，证据等级较高。其创新性在于通过同时抑制 CDK2/4/6 克服 CDK4/6 耐药，为内分泌治疗失败后的患者提供了新的治疗选择。但研究的总体生存数据尚未成熟，仍需进一步随访观察长期获益。

---

## 38. IFIT3通过与LASP1相互作用激活FAK-ERK信号通路促进食管鳞状细胞癌的淋巴结转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413015)
**期刊：** Cell death & disease
**PMID：** 41413015
**DOI：** 10.1038/s41419-025-08327-z

### 第一部分 原文与翻译

**英文原标题：** IFIT3 promotes lymph node metastasis by interacting with LASP1 to activate FAK-ERK signaling in esophageal squamous cell carcinoma.

> **英文摘要：**
> Lymph node metastasis (LNM) is an important cause of poor prognosis in patients with esophageal squamous cell carcinoma (ESCC). However, the mechanism of LNM in ESCC has not been elucidated. Here, we identified interferon-induced proteins with tetratricopeptide repeats 3 (IFIT3) highly expressed in ESCC, especially in LNM tissues. IFIT3 overexpression promoted ESCC cell metastasis in vitro and in vivo. Mechanistically, IFIT3 interacted with LIM and SH3 protein 1 (LASP1) and facilitated the localization of LASP1 to the cell edge, promoting the interaction between LASP1 and Talin1 and the binding of Talin1 to integrin, ultimately activating the FAK-ERK signaling pathway. Clinically, IFIT3 and LASP1 were upregulated in ESCC and LNM tissues and associated with poor prognosis. Moreover, patients with high expression of both IFIT3 and LASP1 have a poorer prognosis. In conclusion, IFIT3 promotes LNM in ESCC through the LASP1/FAK/ERK axis, and IFIT3 is a potential therapeutic target for LNM in ESCC.

> **中文摘要：**
> 淋巴结转移（LNM）是食管鳞状细胞癌（ESCC）患者预后不良的重要原因。然而，ESCC中LNM的机制尚未阐明。本研究发现，干扰素诱导的四螺旋重复蛋白3（IFIT3）在ESCC中高度表达，尤其在LNM组织中表达显著。IFIT3的过表达在体内外均促进了ESCC细胞的转移。机制上，IFIT3与LIM和SH3蛋白1（LASP1）相互作用，促进LASP1定位于细胞边缘，从而增强LASP1与Talin1的相互作用及Talin1与整合素的结合，最终激活FAK-ERK信号通路。在临床上，ESCC及其LNM组织中IFIT3和LASP1水平均上调，并与不良预后相关。此外，同时高表达IFIT3和LASP1的患者预后更差。综上所述，IFIT3通过LASP1/FAK/ERK轴促进ESCC的淋巴结转移，且IFIT3可能是ESCC LNM的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究围绕食管鳞状细胞癌淋巴结转移的分子机制展开，揭示了IFIT3通过调控LASP1及FAK-ERK信号通路促进肿瘤侵袭转移的关键作用。研究结合分子实验与临床样本分析，验证了IFIT3和LASP1的共表达与预后不良之间的关联。该成果在发现新的转移促进因子的同时，为ESCC转移的分子靶向治疗提供了新思路。然而，该研究主要为实验室与组织水平的探索，仍需进一步临床验证以支持其作为治疗靶点的可行性。

---

## 39. 血红素通过激活 STING 促进脓毒症中心脏内皮细胞衰老

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413012)
**期刊：** Cell death & disease
**PMID：** 41413012
**DOI：** 10.1038/s41419-025-08370-w

### 第一部分 原文与翻译

**英文原标题：** Heme drives cardiac endothelial senescence in sepsis via STING activation.

> **英文摘要：**
> Sepsis-induced cardiac dysfunction is a major contributor to sepsis-related mortality, and many patients continue to experience long-term cardiac complications after recovery. Here, we demonstrate that cardiac senescence is a key feature of sepsis-associated cardiac dysfunction, with endothelial cells identified as the predominant senescent population in septic cardiac tissue. However, the pathogenic drivers of endothelial senescence in sepsis remain poorly characterized. Among potential mediators, we found that elevated levels of heme, a byproduct of hemolysis, strongly correlate with increased endothelial senescence and impaired cardiac function. Mechanistic studies revealed that heme acts as a novel ligand for STING, exacerbating bacterial infection-induced STING polymerization and activation, thereby promoting endothelial senescence. Notably, either STING inhibition or enhanced heme clearance via increased hemopexin expression significantly alleviated cardiac endothelial senescence and facilitated cardiac functional recovery in septic mice. These findings identify heme as a critical pathogenic driver of endothelial senescence and highlight heme clearance as a promising therapeutic strategy for mitigating sepsis-induced cardiac dysfunction.

> **中文摘要：**
> 脓毒症诱导的心脏功能障碍是导致脓毒症相关死亡的主要原因之一，许多患者在康复后仍持续出现长期心脏并发症。在本研究中，我们证明心脏衰老是脓毒症相关心脏功能障碍的关键特征，其中内皮细胞是脓毒症心脏组织中主要的衰老细胞群。然而，脓毒症中心内皮细胞衰老的致病驱动因素仍不清楚。在潜在介质中，我们发现溶血副产物血红素水平升高与内皮衰老增加及心功能受损密切相关。机制研究表明，血红素作为 STING 的新型配体，可加剧细菌感染诱导的 STING 聚合和激活，从而促进内皮细胞衰老。值得注意的是，无论是抑制 STING，还是通过增加血红素结合蛋白表达以增强血红素清除，都能显著缓解脓毒症小鼠的心内皮衰老并促进心功能恢复。这些发现揭示血红素是导致内皮细胞衰老的关键致病因素，并提示血红素清除可能成为减轻脓毒症相关心脏功能障碍的潜在治疗策略。

### 第二部分 AI 大师评价

该研究聚焦于脓毒症相关心脏损伤的分子机制，发现血红素通过激活 STING 信号通路驱动心脏内皮细胞衰老，从而加重心功能障碍。研究采用动物模型和分子机制分析，从代谢副产物与先天免疫信号交互的角度提出新机制。通过 STING 抑制或强化血红素清除改善心脏功能，为脓毒症心脏保护提供新治疗思路。创新性在于揭示血红素—STING 轴的致病作用，但仍需临床研究验证其可转化潜力。

---

## 40. 益生菌发酵乳制品对海马代谢物、结构和功能的影响：一项为期8周的随机、安慰剂对照试验（健康女性）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41412728)
**期刊：** Gut
**PMID：** 41412728
**DOI：** 10.1136/gutjnl-2025-335398

### 第一部分 原文与翻译

**英文原标题：** Effects of a probiotic fermented dairy product on hippocampal metabolites, structure and function: an 8-week randomised, placebo-controlled trial in healthy women.

> **英文摘要：**
> BACKGROUND: Fermented foods are a promising yet underexplored intervention for influencing brain function and mental health through the gut-brain axis.
> 
> OBJECTIVE: The objective of this study was to evaluate the impact of a dairy product fermented with probiotic bacteria on aspects of brain structure and function.
> 
> DESIGN: In a triple-blind, randomised, placebo-controlled trial, 40 healthy women aged 18-55 years were randomised to consume either 130 g per day of a fermented probiotic yoghurt or a placebo for 8 weeks. The primary outcome was the between-group differential change from baseline to week 8 in left hippocampal metabolites, measured using magnetic resonance spectroscopy. Secondary outcomes included changes in brain structure and function, faecal microbiome composition and functional potential, mental health, gastrointestinal symptoms, memory and blood markers of oxidative stress and inflammation.
> 
> RESULTS: There was a between-group difference in the change in average left hippocampal glutathione concentration (mean difference in change: -0.49; 95% CI -0.95 to -0.04), as well as brain volume in the hippocampus and nucleus accumbens, although these results did not withstand correction for multiple comparisons. There were between-group differences in the change in average functional connectivity between the left hippocampus and left frontal pole. There was also a significant between-group change in gut microbiome beta diversity. There were no differences in other secondary measures.
> 
> CONCLUSION: This study provides preliminary evidence that a probiotic fermented dairy product can modulate hippocampal-related outcomes.
> 
> TRIAL REGISTRATION NUMBER: ACTRN12622000622707.

> **中文摘要：**
> 背景：发酵食品是通过肠–脑轴影响脑功能和心理健康的一种具有潜力但尚未充分研究的干预手段。
> 
> 目的：本研究旨在评估一种由益生菌发酵的乳制品对脑结构和功能各方面的影响。
> 
> 设计：本研究为三盲、随机、安慰剂对照试验，共纳入40名18至55岁的健康女性，随机分配为每日摄入130克益生菌发酵酸奶或安慰剂，持续8周。主要结局为8周内左海马代谢物的组间差异性变化，采用磁共振波谱测定。次要结局包括脑结构和功能变化、粪便微生物群组成及功能潜力、心理健康状况、胃肠道症状、记忆功能、以及血液中氧化应激与炎症标志物的变化。
> 
> 结果：组间在左海马谷胱甘肽平均浓度变化上存在差异（平均变化差异：-0.49；95%置信区间：-0.95至-0.04），同时在海马体和伏隔核脑体积方面也观察到差异，但这些结果在多重比较校正后未达显著。左海马与左额极之间功能连接的平均变化亦存在组间差异。此外，肠道微生物群β多样性也显示出显著的组间变化。其他次要指标未观察到明显差异。
> 
> 结论：本研究提供了初步证据，提示益生菌发酵乳制品可能调节与海马相关的脑功能结果。
> 
> 试验注册号：ACTRN12622000622707。

### 第二部分 AI 大师评价

本研究是首个以随机、三盲、安慰剂对照设计系统评估益生菌发酵乳制品对脑部代谢及结构功能影响的临床试验之一。通过磁共振波谱及影像学分析，研究发现该干预可能影响海马谷胱甘肽水平及脑区间功能连接。结果提示益生菌发酵食品具有通过肠–脑轴调节脑功能的潜力，但统计学稳健性仍需在更大样本及更长随访期中验证。该研究在方法学上严谨，开创性地将脑成像指标与肠道菌群变化相结合，为营养精神医学提供了新的研究方向。

---

## 41. 肠道菌群生成的继发性胆汁酸促进与西方饮食相关的结直肠癌发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41412727)
**期刊：** Gut
**PMID：** 41412727
**DOI：** 10.1136/gutjnl-2024-332243

### 第一部分 原文与翻译

**英文原标题：** Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer.

> **英文摘要：**
> BACKGROUND: Western diet and associated production of secondary bile acids (BAs) have been linked to the development of sporadic colorectal cancer (CRC). Despite observational studies showing that secondary BAs produced by 7α-dehydroxylating (7αDH+) gut bacteria are increased in CRC, a causal proof of their tumour-promoting effects is lacking.
> 
> OBJECTIVE: Investigate the causal role of BAs produced by 7αDH+ gut bacteria in CRC.
> 
> DESIGN: We performed feeding studies in a porcine model of CRC combined with multi-omics analyses and gnotobiotic mouse models colonised with 7αDH+ bacteria or a genetically modified strain to demonstrate causality.
> 
> RESULTS: Western diet exacerbated the CRC phenotype in pigs. This was accompanied by increased levels of the secondary BA deoxycholic acid (DCA) and higher colonic epithelial cell proliferation. The latter was counteracted by the BA-scavenging drug colestyramine. Metagenomic analysis across multiple human cohorts revealed higher occurrence of (BA inducible) operons from and close relatives in faeces of patients with CRC. Addition of these specific 7αDH+ bacteria (/) to defined communities of gut bacteria led to DCA production and increased colon tumour burden in mouse models of chemically or genetically induced CRC. A mutant strain of lacking 7αDH caused fewer colonic tumours in azoxymethane/dextran sodium sulfate treated mice and triggered less epithelial cell proliferation in human colon organoids compared with wild-type.
> 
> CONCLUSION: This work provides functional evidence for the causal role of secondary BAs produced by gut bacteria through 7αDH in CRC under adverse dietary conditions, opening avenues for future preventive strategies.

> **中文摘要：**
> 背景：西方饮食及其相关的继发性胆汁酸（BAs）生成与散发性结直肠癌（CRC）的发生相关。尽管观察性研究显示由7α-脱羟化（7αDH+）肠道细菌产生的继发性胆汁酸在CRC中升高，但其促肿瘤作用的因果证据仍然不足。
> 
> 目的：探讨由7αDH+肠道细菌生成的胆汁酸在CRC中的因果作用。
> 
> 设计：我们在猪的CRC模型中开展喂养实验，并结合多组学分析及定植有7αDH+菌株或基因修饰菌株的无菌小鼠模型，以验证其因果关系。
> 
> 结果：西方饮食加剧了猪的CRC表型；同时伴随继发性胆汁酸脱氧胆酸（DCA）水平升高及结肠上皮细胞增殖增强。后者可被胆汁酸清除药考来烯胺（colestyramine）抵消。多个人群的宏基因组分析显示，CRC患者粪便中源自某些菌属及其近缘种的（胆汁酸诱导性）操纵子出现频率更高。将特定7αDH+细菌（/）加入已定义的肠道菌群群落，可导致DCA生成并增加化学诱导或基因诱导CRC小鼠模型中的结肠肿瘤负担。相比野生型菌株，缺失7αDH功能的突变菌株在接受偶氮甲烷/右旋糖硫酸钠处理的小鼠中引起更少的结肠肿瘤，并在人体结肠类器官中导致更低的上皮细胞增殖。
> 
> 结论：本研究为在不良饮食条件下由肠道细菌通过7αDH生成的继发性胆汁酸在CRC中发挥因果作用提供了功能性证据，为未来的预防策略提供了新方向。

### 第二部分 AI 大师评价

该研究系统揭示了由7α-脱羟化肠道细菌生成的继发性胆汁酸在西方饮食促进结直肠癌发生中的因果作用。通过猪模型、多组学分析及无菌小鼠验证实验，作者提供了从机制到功能的多层次证据。研究发现脱氧胆酸上调及相关菌群变化与肿瘤表型加剧密切相关，并可被胆汁酸清除剂逆转。该工作创新地建立了饮食—微生物代谢—宿主癌变之间的因果链，为结直肠癌预防提供了潜在干预靶点，但仍需进一步阐明具体的分子机制与临床可转化路径。

---

## 42. 综合空间分析揭示卵巢癌前病变的分子图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411622)
**期刊：** Cancer research
**PMID：** 41411622
**DOI：** 10.1158/0008-5472.CAN-25-3189

### 第一部分 原文与翻译

**英文原标题：** Integrated Spatial Analysis Reveals the Molecular Landscape of Ovarian Precancerous Lesions.

> **英文摘要：**
> Studying precancerous lesions is essential for improving early detection and prevention, particularly in aggressive cancers such as ovarian carcinoma. Here, we conducted integrated and spatial analyses of transcriptomes, aneuploidy, and clinicopathological features in 166 ovarian precancerous lesions. Four pre-cancerous transcriptomic subtypes were identified: proliferative, immunoreactive, dormant, and mixed. These subtypes varied in their frequency of germline-BRCA1/2 mutations, aneuploidy, CCNE1/MYC amplification, proliferative activity, immune-regulatory gene expression, and histological features. Notably, the immunoreactive subtype upregulated immune-regulatory genes, exhibited chronic inflammation, and was enriched in cases with germline-BRCA1/2 mutations, deletions of chromosomes 17 (harboring TP53 and BRCA1) and 13 (harboring BRCA2), leading to a double "two-hit" involving TP53 and BRCA1/2. Tumor invasion was associated with the activation of interferon response pathways, epithelial-mesenchymal transition, and extracellular matrix remodeling. In summary, these results elucidate the earliest molecular landscape of ovarian precancerous lesions, serving as the foundation for future risk stratification to identify aggressive pre-cancerous lesions.

> **中文摘要：**
> 研究癌前病变对于改进早期检测与预防具有重要意义，尤其针对卵巢癌等侵袭性肿瘤。本研究对166例卵巢癌前病变的转录组、非整倍体状态及临床病理特征进行了综合与空间分析。结果鉴定出四种癌前转录组亚型：增殖型、免疫反应型、休眠型及混合型。这些亚型在生殖系BRCA1/2突变频率、非整倍体程度、CCNE1/MYC扩增、增殖活性、免疫调节基因表达及组织学特征方面存在差异。值得注意的是，免疫反应型亚型表现为免疫调节基因上调、慢性炎症，并富集于存在生殖系BRCA1/2突变、17号染色体（携带TP53与BRCA1）及13号染色体（携带BRCA2）缺失的病例中，从而形成涉及TP53与BRCA1/2的双重“双打击”机制。肿瘤侵袭与干扰素反应通路激活、上皮-间质转化以及细胞外基质重塑有关。综上所述，本研究揭示了卵巢癌前病变的最早分子图谱，为未来的风险分层和识别高侵袭性癌前病变奠定了基础。

### 第二部分 AI 大师评价

本研究通过多维整合和空间分析，系统描绘了卵巢癌前病变的分子分型与空间特征，揭示其早期肿瘤发生的异质性机制。研究团队定义了四种转录组亚型，并发现免疫反应型与BRCA1/2缺失及炎症反应密切相关，为理解卵巢癌早期演变提供了关键线索。其创新性在于首次将空间组学与基因组不稳定性相结合，构建癌前分子景观。然而，样本来源局限于癌前阶段，仍需纵向研究验证其对实际癌变风险预测的价值。

---

## 43. 整合性CRISPR筛选与RNA分析揭示PUF60与3'剪接位点相互作用在癌症进展中的关键作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411621)
**期刊：** Cancer research
**PMID：** 41411621
**DOI：** 10.1158/0008-5472.CAN-25-0453

### 第一部分 原文与翻译

**英文原标题：** Integrative CRISPR Screening and RNA Analyses Discover an Essential Role for PUF60 Interactions with 3' Splice Sites in Cancer Progression.

> **英文摘要：**
> RNA-binding proteins (RBPs) are important regulators of post-transcriptional gene expression. Understanding which and how RBPs promote cancer progression is crucial for cancers that lack effective targeted therapies, such as triple negative breast cancer (TNBC). Here, we employed both in vitro and in vivo pooled CRISPR/Cas9 screening to identify 50 RBP candidates essential for TNBC cell survival. Integrated eCLIP and RNA-sequencing analysis identified that poly(U)-binding splicing factor 60 (PUF60) drives exon inclusion within proliferation-associated transcripts that, when mis-spliced, induce cell cycle arrest and DNA damage. Furthermore, disrupting PUF60 interactions with 3' splice sites via a substitution in its RNA-binding domain caused widespread exon skipping, leading to downregulation of proliferation-associated mRNAs and inducing apoptosis in TNBC cells. Knockdown of PUF60 or disruption of PUF60-RNA interactions inhibited TNBC cell proliferation and shrunk tumor xenografts in multiple models. Together, these findings reveal the molecular mechanism by which PUF60 supports cancer progression.

> **中文摘要：**
> RNA结合蛋白（RBP）是转录后基因表达的重要调控因子。了解哪些RBP以及其促进癌症进展的机制，对于缺乏有效靶向疗法的癌症（如三阴性乳腺癌，TNBC）至关重要。本研究在体内外采用了汇集型CRISPR/Cas9筛选，鉴定出50个对TNBC细胞生存至关重要的RBP候选基因。整合eCLIP与RNA测序分析发现，poly(U)-结合剪接因子60（PUF60）可驱动增殖相关转录本的外显子包含，而当这些外显子发生错误剪接时，会导致细胞周期停滞和DNA损伤。此外，通过在PUF60的RNA结合域中进行取代以破坏其与3'剪接位点的相互作用，会引起广泛的外显子跳跃，进而下调增殖相关mRNA的表达并诱导TNBC细胞发生凋亡。敲低PUF60或破坏PUF60-RNA相互作用均可抑制TNBC细胞增殖，并在多种模型中导致异种移植瘤缩小。总体而言，这些研究结果揭示了PUF60支持癌症进展的分子机制。

### 第二部分 AI 大师评价

该研究结合CRISPR/Cas9功能筛选与eCLIP-RNA测序分析，系统性地揭示了RNA结合蛋白PUF60在三阴性乳腺癌中的关键作用。作者发现PUF60通过维持增殖相关转录本的正常剪接促进肿瘤细胞生存，其相互作用的破坏导致癌细胞凋亡和肿瘤缩减。该研究创新性地将剪接调控网络与癌症功能依赖性相结合，为难治型乳腺癌提供了潜在的新靶点。然而，未来仍需进一步探明PUF60在其他癌种及临床样本中的作用机制及其可药性潜力。

---

## 44. 小细胞肺癌的分类：揭示异质性以实现个体化治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411619)
**期刊：** Cancer research
**PMID：** 41411619
**DOI：** 10.1158/0008-5472.CAN-25-1483

### 第一部分 原文与翻译

**英文原标题：** Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments.

> **英文摘要：**
> Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for SCLC patients remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. Since SCLC subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the last ten years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC as well as potential future directions for SCLC research.

> **中文摘要：**
> 小细胞肺癌（SCLC）是一种侵袭性极强的胸部肿瘤疾病，其特征为快速增殖和早期转移。SCLC 患者的生存结局仍然极为不理想，表明至今在临床方面仅取得了有限的改善。然而，近年来来源于人类肿瘤样本和临床前模型的研究揭示了 SCLC 的分子异质性特征。据此，众多研究团队开始根据转录因子表达差异、肿瘤免疫微环境及其他标准，将 SCLC 进行亚型分层。由于不同 SCLC 亚型在分子景观与生物学行为上存在显著差异，这些亚型可能代表独特的治疗脆弱点，并为未来个体化临床试验提供框架。本文总结了近十年来具有影响力的分类研究，重点强调了不同研究命名体系之间的差异与联系，并阐述了影响亚型组成和可塑性的相关 SCLC 生物学因素。本综述还探讨了亚型划分对理解与治疗 SCLC 的启示以及未来研究可能的发展方向。

### 第二部分 AI 大师评价

该综述旨在系统总结过去十年来小细胞肺癌（SCLC）分型研究的主要进展，重点剖析其分子异质性及亚型生物学特征。作者通过比较不同研究的分类标准与命名体系，揭示其一致性与差异性，并讨论了亚型相关的肿瘤生物学机制。文章的创新在于综合不同研究视角，提出将分子亚型作为个体化治疗与临床试验设计基础的框架。其局限在于，目前多数分型仍停留在研究阶段，临床应用验证尚需进一步推进。

---

## 45. 溶瘤性HSV-1介导的JAG1阻断诱导胶质瘤衰老相关分泌表型，从而增强巨噬细胞活化并促进西妥昔单抗介导的清除衰老细胞作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411618)
**期刊：** Cancer research
**PMID：** 41411618
**DOI：** 10.1158/0008-5472.CAN-25-1402

### 第一部分 原文与翻译

**英文原标题：** Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis.

> **英文摘要：**
> Oncolytic HSV-1 (oHSV) treatment induces Notch signaling and myelosuppression in the tumor microenvironment (TME) of preclinical cancer models. Clinically, the Notch ligand JAG1 was upregulated in recurrent high-grade glioma patients treated with the oHSV CAN-3110 and correlated with poor prognosis. To better understand endogenous JAG1-mediated signaling in glioma cells and tumor-associated macrophages (TAMs), we engineered a JAG1-antagonizing oHSV (OD-0J1) and interrogated its impact on cancer and myeloid cells in the tumor microenvironment. OD-0J1 antagonized JAG1-mediated Notch signaling and suppressed tumor growth in athymic nude and humanized mice, an effect reliant on Notch signaling in tumor cells. Kinome profiling revealed that OD-0J1 treatment suppressed CDK1, resulting in activation of the G2/M cell cycle checkpoint. Cell cycle arrest led to senescence and correlated with increased reactive oxygen species, p62 and autophagosome accumulation, and senescence-associated β-galactosidase activity. OD-0J1-induced senescence resulted in increased production of inflammatory chemokines and DAMPs, such as IL-1β, HMGB1, and extracellular ATP. Co-culturing macrophages with OD-0J1-infected tumor cells led to stimulation of chemotactic and pro-inflammatory pathways, as well as increased Fc receptor activation. Single-cell RNA sequencing and flow cytometric analysis of F4/80+ cells isolated from tumors showed a shift from tumor-supporting TAMs to inflammatory macrophages upon OD-0J1 treatment. Heightened EGFR activation in senescent cells was a mechanism to escape cell death, which created a unique opportunity for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the anti-tumor therapeutic efficacy of OD-0J1.

> **中文摘要：**
> 在临床前癌症模型的肿瘤微环境（TME）中，溶瘤性HSV-1（oHSV）治疗可诱导Notch信号通路和骨髓抑制。临床上，在接受oHSV CAN-3110治疗的复发性高级别胶质瘤患者中，Notch配体JAG1上调，并与不良预后相关。为更好地理解胶质瘤细胞及肿瘤相关巨噬细胞（TAMs）内源性JAG1介导的信号传导，我们构建了一种拮抗JAG1的oHSV（OD-0J1），并探究其在肿瘤微环境中对癌细胞和髓系细胞的作用。OD-0J1抑制JAG1介导的Notch信号，并在无胸腺裸鼠和人源化小鼠中抑制肿瘤生长，该效应依赖于肿瘤细胞中的Notch信号。激酶组分析显示，OD-0J1治疗抑制CDK1，从而激活G2/M细胞周期检查点。细胞周期停滞导致细胞衰老，并与活性氧（ROS）增加、p62及自噬小体积累以及衰老相关β-半乳糖苷酶活性增强相关。OD-0J1诱导的衰老导致炎性趋化因子和损伤相关分子模式（DAMPs）如IL-1β、HMGB1和细胞外ATP的产生增加。将巨噬细胞与OD-0J1感染的肿瘤细胞共培养，可激活趋化及促炎信号通路，并增强Fc受体活化。单细胞RNA测序及从肿瘤中分离出的F4/80+细胞的流式细胞术分析显示，OD-0J1治疗使TAMs由支持肿瘤型向促炎型巨噬细胞转化。在衰老细胞中EGFR活化增强是一种逃避细胞死亡的机制，这为将西妥昔单抗作为去衰老药物提供了独特机会。联合治疗降低EGFR信号并诱导巨噬细胞介导的抗体依赖性细胞毒作用，从而提高了OD-0J1的抗肿瘤治疗效能。

### 第二部分 AI 大师评价

本研究通过创新性地构建JAG1拮抗型溶瘤病毒OD-0J1，揭示其可通过阻断Notch信号诱导胶质瘤细胞衰老及相关分泌表型，从而激活促炎巨噬细胞并增强免疫杀伤。研究进一步发现，EGFR通路在衰老细胞中具有逃生作用，而西妥昔单抗可作为特异性去衰老药物与OD-0J1协同提高疗效。该工作不仅丰富了对溶瘤病毒免疫调控机制的理解，也为胶质瘤治疗提供了新型病毒-抗体联合策略，然而仍需在临床模型中验证其安全性与普适性。

---

## 46. AQP5：一种在小鼠和人类肿瘤中具有功能性的胃癌干细胞标志物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411445)
**期刊：** Science (New York, N.Y.)
**PMID：** 41411445
**DOI：** 10.1126/science.adr2428

### 第一部分 原文与翻译

**英文原标题：** AQP5: A functional gastric cancer stem cell marker in mouse and human tumors.

> **英文摘要：**
> Cancer stem cells (CSCs) represent a self-renewing population capable of fueling long-term tumor growth. In gastric cancer, the identity of CSC populations remains unclear. In this study, we established a gastric CSC population marked by the water channel protein aquaporin-5 (AQP5), which resides in human and mouse pyloric tumors. Using multiple organoid and mouse models, we found a requirement for AQP5 CSCs in both initiating and sustaining cancer progression and demonstrated that AQP5 expression also directly promotes tumor growth and invasion in a WNT, PI3K (phosphatidylinositol 3-kinase), and MAPK (mitogen-activated protein kinase)-dependent manner. Beyond primary cancers, AQP5 further enriches for a functional CSC population in metastatic tumors. Together, our findings support a CSC model in gastric tumors that may have application for therapeutic strategies targeting CSCs.

> **中文摘要：**
> 癌症干细胞（CSCs）代表一种具有自我更新能力、能够驱动肿瘤长期生长的细胞群体。在胃癌中，CSC群体的具体身份仍不明确。在本研究中，我们建立了一种由水通道蛋白aquaporin-5（AQP5）标记的胃CSC群体，该群体存在于人类和小鼠的幽门部肿瘤中。通过多个类器官和小鼠模型，我们发现AQP5阳性的CSC对于肿瘤发生与进展的启动和维持均是必需的，并证明AQP5的表达还能通过依赖WNT、PI3K（磷脂酰肌醇3-激酶）和MAPK（丝裂原活化蛋白激酶）信号通路的方式直接促进肿瘤的生长与侵袭。除原发癌外，AQP5还在转移性肿瘤中富集出具有功能性的CSC群体。总体而言，我们的研究结果支持胃癌中存在一种CSC模型，这一模型可能为针对CSC的治疗策略提供潜在应用。

### 第二部分 AI 大师评价

该研究通过在小鼠与人类模型中鉴定AQP5阳性的胃癌干细胞群体，为胃癌干细胞的功能标志物提供了新的生物学证据。利用类器官和动物实验，作者阐明了AQP5在肿瘤启动与持续进展中的关键作用，并揭示其通过WNT、PI3K和MAPK信号通路促进肿瘤生长和侵袭。该成果在肿瘤干细胞研究及精准治疗靶点发现方面具有创新性。然而，AQP5在不同分型胃癌中的普适性及临床转化仍需进一步验证。

---

## 47. 染色质在转录过程中缓冲扭转应力。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411413)
**期刊：** Science (New York, N.Y.)
**PMID：** 41411413
**DOI：** 10.1126/science.adv0134

### 第一部分 原文与翻译

**英文原标题：** Chromatin buffers torsional stress during transcription.

> **英文摘要：**
> During eukaryotic transcription, Pol II must overcome nucleosome obstacles and, because of DNA's helical structure, must also rotate relative to DNA, generating torsional stress. However, there is limited understanding of how Pol II transcribes through nucleosomes while supercoiling DNA. Here, we determined that Pol II generates a torque of 9 pN·nm alone and 13 pN·nm with TFIIS, making it a powerful rotary motor. When Pol II encounters a nucleosome, passage becomes more efficient on a chromatin substrate than on a single-nucleosome substrate, demonstrating that chromatin significantly buffers torsional stress during transcription. Furthermore, topoisomerase supercoiling relaxation allows Pol II to transcribe through multiple nucleosomes. Our results reveal a role of chromatin beyond the more conventional view of it being just a roadblock to transcription.

> **中文摘要：**
> 在真核转录过程中，RNA 聚合酶 II（Pol II）必须克服核小体的障碍，并且由于 DNA 的螺旋结构，还必须相对于 DNA 发生旋转，从而产生扭转应力。然而，对于 Pol II 在超螺旋化 DNA 的同时如何通过核小体的机制，目前了解仍然有限。本研究确定，Pol II 单独能够产生 9 pN·nm 的扭矩，而在存在 TFIIS 时可达到 13 pN·nm，使其成为一种强大的旋转分子马达。当 Pol II 遇到核小体时，在染色质底物上的通过效率高于单个核小体底物，这表明染色质在转录过程中显著缓冲了扭转应力。此外，拓扑异构酶介导的超螺旋松弛使 Pol II 能够穿越多个核小体。我们的结果揭示了染色质除传统意义上的“转录障碍”之外的另一重要作用。

### 第二部分 AI 大师评价

该研究旨在探讨 RNA 聚合酶 II 在真核转录过程中如何应对 DNA 的扭转应力及核小体障碍。研究者通过定量测量 Pol II 的扭矩并比较其在不同底物上的转录效率，揭示了染色质在转录过程中具有缓冲扭转应力的功能。结果显示，Pol II 是一种高效旋转分子马达，而染色质结构显著优化了其转录过程。该工作创新性地将染色质的作用从“静态屏障”拓展为“动态应力缓冲体系”，但未来仍需探讨不同类型染色质的力学特性及其调控机制。

---

## 48. 利用半透胶囊实现高通量单细胞组学分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411411)
**期刊：** Science (New York, N.Y.)
**PMID：** 41411411
**DOI：** 10.1126/science.ady7227

### 第一部分 原文与翻译

**英文原标题：** High-throughput single cell omics using semipermeable capsules.

> **英文摘要：**
> Biological systems are inherently complex and heterogeneous. Deciphering this complexity increasingly relies on high-throughput single-cell omics methods and tools that efficiently probe the cellular phenotype and genotype. Here we present a versatile technology based on semipermeable capsules (SPCs), tailored for a variety of high-throughput nucleic acid assays, including single-cell genome and mRNA sequencing, and fluorescence-activated cell sorting-based isolation of individual transcriptomes based on nucleic acid marker of interest. Being biocompatible, the SPCs support single-cell cultivation and clonal expansion over long periods of time thereby overcoming a fundamental limitation of droplet microfluidics platforms. Overall, the SPCs represent customizable and broadly applicable tool for easy-to-use, scalable single-cell omics applications that are built on multi-step biochemical reactions.

> **中文摘要：**
> 生物体系本质上具有复杂性和异质性。对这种复杂性的解析越来越依赖于高通量的单细胞组学方法和工具，以高效探测细胞表型和基因型。在此，我们提出了一种基于半透胶囊（SPCs）的多功能技术，适用于多种高通量核酸分析，包括单细胞基因组和mRNA测序，以及基于荧光激活细胞分选的、依赖特定核酸标记的单细胞转录组分离。由于具有良好的生物相容性，SPCs可支持单细胞的长期培养和克隆扩增，从而克服了液滴微流控平台的根本限制。总体而言，SPCs为基于多步生化反应的单细胞组学应用提供了一种可定制、易于使用且具有广泛适用性的可扩展工具。

### 第二部分 AI 大师评价

本研究提出了一种基于半透胶囊的高通量单细胞组学新平台，旨在同时改善核酸检测、单细胞培养与筛选效率。作者展示了该技术在单细胞基因组和转录组测序中的广泛兼容性，并通过生物相容性设计解决了传统液滴微流控长期培养受限的问题。这一方法的创新在于在封闭可控的胶囊环境中实现多步生化反应与细胞扩增的整合，具有良好的可扩展性和应用潜力。其局限可能在于制造复杂度及与不同细胞类型的通用性仍需进一步验证。

---

## 49. 骨髓瘤循环肿瘤细胞是反映骨髓高风险基因组改变与肿瘤负荷的复合生物标志物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411148)
**期刊：** Blood
**PMID：** 41411148
**DOI：** 10.1182/blood.2025030083

### 第一部分 原文与翻译

**英文原标题：** Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.

> **英文摘要：**
> High levels of circulating tumor cells (CTC) are a powerful predictor of poor outcomes in newly diagnosed multiple myeloma, yet the mechanistic underpinnings of this correlation remain unknown. To investigate whether CTC-related pathobiology is driven by a specific circulating tumor cell subset, paired bone marrow and blood samples from newly-diagnosed multiple myeloma patients were analyzed by single-cell transcriptomics and whole-genome sequencing. This revealed that down to the individual clone level, CTCs and paired bone marrow cells are transcriptionally similar, without evidence for a distinct circulating population. In contrast, bone marrow myeloma cells from patients with high CTC levels showed increased proliferation and unbalanced primary genetic events, including enrichment for MAF and CCND translocations. To investigate impact of heterogenic genomic events on CTC levels, whole-exome and bulk-RNA sequencing from the MMRF CoMMpass dataset were analyzed and validated in our in-house datasets. Bone marrow tumor cells from patients with high CTC levels were uniformly characterized by transcriptomic signatures of proliferation. Additionally, CTC levels were uniquely dependent on primary genomic events, as well as high-risk secondary genomic events, including amplification1q, deletion1p, deletion13q, biallelic TP53 mutations, and increased APOBEC-induced mutations even in patients without MAF translocations. Finally, we developed a model that predicts the impact of genetic alterations and tumor burden on CTC levels. In sum, we show that CTC are the net result of tumor burden, primary translocations, and secondary genomic events, making CTC a powerful biomarker for genomics-driven high-risk disease in newly diagnosed myeloma patients.

> **中文摘要：**
> 高水平的循环肿瘤细胞（CTC）是新诊断多发性骨髓瘤患者不良预后的有力预测指标，但这种相关性的机制基础仍然未知。为探讨CTC相关病理生物学是否由特定的循环肿瘤细胞亚群驱动，研究者采用单细胞转录组测序和全基因组测序分析了新诊断多发性骨髓瘤患者的成对骨髓和外周血样本。结果显示，在单个克隆水平上，CTC与对应骨髓细胞在转录水平上高度相似，未发现独立的循环细胞群体。相反，CTC水平较高的患者骨髓髓瘤细胞表现出增殖活性增强及原发性遗传事件的不平衡，包括MAF和CCND易位的富集。为研究异质性基因组事件对CTC水平的影响，研究者分析了MMRF CoMMpass数据库中的全外显子与整体RNA测序数据，并在自建数据集中进行了验证。CTC水平较高患者的骨髓肿瘤细胞普遍呈现出增殖型转录组特征。此外，CTC水平不仅依赖于原发性基因组事件，还依赖于高风险继发性基因组事件，包括1q扩增、1p缺失、13q缺失、TP53双等位突变以及在无MAF易位患者中也出现的APOBEC诱导突变的增加。最后，研究者建立了一个模型，用于预测基因改变量和肿瘤负荷对CTC水平的影响。总之，本研究表明CTC水平反映了肿瘤负荷、原发易位和继发基因组事件的综合结果，使CTC成为新诊断骨髓瘤患者基因组驱动的高风险疾病的强效生物标志物。

### 第二部分 AI 大师评价

本研究聚焦于多发性骨髓瘤中循环肿瘤细胞（CTC）的生物学意义，旨在揭示其与基因组风险特征及肿瘤负荷的关系。通过单细胞、多组学及大型数据库分析，研究表明CTC与骨髓瘤细胞在转录上高度相似，CTC水平主要反映了肿瘤增殖及特定基因组事件的影响。作者进一步提出模型，综合预测基因改变与肿瘤负荷对CTC水平的影响。研究创新地将CTC定义为复合性生物标志物，为多发性骨髓瘤的风险评估与精准分层提供了新思路，但其模型仍需在多中心临床队列中进一步验证。

---

## 50. HLA 配型外周血造血干细胞移植中移植后环磷酰胺的应用：下一步是什么？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41411147)
**期刊：** Blood
**PMID：** 41411147
**DOI：** 10.1182/blood.2025030416

### 第一部分 原文与翻译

**英文原标题：** Posttransplant Cyclophosphamide in HLA-matched Peripheral Blood Transplantation: What's next?

> **英文摘要：**
> The use of post-transplant cyclophosphamide was initially pioneered as a means of permitting haploidentical transplantation across HLA barriers. This approach has now become a standard of care for the prevention of significant acute and chronic GVHD after related and unrelated HLA-matched allogeneic peripheral blood stem cell transplant across a full spectrum of conditioning intensities. This spotlight article discusses recent advances, mechanisms of action, and important unresolved questions in the prevention of GVHD that will help inform new prospective clinical studies.

> **中文摘要：**
> 移植后使用环磷酰胺最初是作为一种跨越 HLA 屏障、实现半相合移植的方法而被开创的。该策略现已成为一个标准方案，用于在不同预处理强度下的有关或无关 HLA 配型异基因外周血造血干细胞移植中预防严重的急性和慢性移植物抗宿主病（GVHD）。这篇专题文章探讨了 GVHD 预防领域的最新进展、作用机制以及尚未解决的重要问题，这些内容将有助于指导新的前瞻性临床研究。

### 第二部分 AI 大师评价

本文综述了 HLA 配型外周血造血干细胞移植中移植后环磷酰胺（PTCy）的临床进展与科学问题。该方法最初用于半相合移植，如今已成为预防 GVHD 的主流策略。作者进一步讨论了其免疫学作用机制及未来研究方向。文章具有重要的综述价值，但仍需通过前瞻性临床试验证实不同条件下的最佳应用策略。

---

## 51. 当利妥昔单抗/吉西他滨/奥沙利铂谢幕之时，双特异性抗体崛起：SUNMO 试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41248436)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41248436
**DOI：** 10.1200/JCO-25-02197

### 第一部分 原文与翻译

**英文原标题：** Sun Sets on Rituximab/Gemcitabine/Oxaliplatin as Bispecific Antibodies Rise: The SUNMO Trial.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本文标题暗示传统的利妥昔单抗联合化疗方案逐渐被创新性的双特异性抗体疗法所取代。尽管缺乏正式摘要，研究可能聚焦于评估一种新型双特异抗体在B细胞淋巴瘤或类似血液肿瘤中的临床表现。其创新点在于药物机制更新与治疗策略转变，反映免疫治疗从单靶点向双靶点的演进。然而，目前信息有限，研究结果及其临床意义尚待进一步披露。

---

## 52. 勘误：老年系统性肿瘤治疗患者脆弱性评估与管理的实用指南——ASCO 指南更新。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41237358)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41237358
**DOI：** 10.1200/JCO-25-02598

### 第一部分 原文与翻译

**英文原标题：** Erratum: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文为《老年患者接受系统性癌症治疗脆弱性评估与管理的 ASCO 指南更新》的勘误通知，旨在修正先前版本中的错误或遗漏。虽然未提供摘要，但可推断该勘误涉及临床实践指南的重要更正，确保临床应用的准确性与可靠性。此类更正体现了学术出版的严谨态度，对维持指南科学性与可操作性具有重要意义。

---

## 53. 抗体-药物偶联物与双特异性抗体在淋巴瘤中的应用：权宜之计还是完美搭档？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41202195)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41202195
**DOI：** 10.1200/JCO-25-02200

### 第一部分 原文与翻译

**英文原标题：** Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该论文旨在探讨抗体-药物偶联物（ADCs）与双特异性抗体（BsAbs）在淋巴瘤治疗中的互补性与协同潜力。标题隐含作者试图评估两类新型靶向药物在疗效、耐药机制及临床应用策略方面的契合度。尽管暂无摘要，但可推测其核心关注点在于优化免疫靶向治疗组合，从而提升疗效并降低毒性。该研究具有重要的临床与转化意义，但仍需后续数据验证其实际综合价值。

---

## 54. Glofitamab联合Polatuzumab Vedotin在复发/难治性大B细胞淋巴瘤（包括高级别B细胞淋巴瘤）中的疗效与安全性：Ib/II期临床试验结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41115257)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41115257
**DOI：** 10.1200/JCO-25-00992

### 第一部分 原文与翻译

**英文原标题：** Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

> **英文摘要：**
> PURPOSE: An unmet need remains for more effective therapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), especially high-grade B-cell lymphoma (HGBCL). We present the primary analysis of a phase Ib/II study (ClinicalTrials.gov identifier: NCT03533283) investigating efficacy and safety of glofitamab plus polatuzumab vedotin (Glofit-Pola) in patients with R/R LBCL, including HGBCL and those who received previous chimeric antigen receptor (CAR) T-cell therapy.
> 
> METHODS: Patients received 1,000 mg obinutuzumab on Cycle (C)1 Day (D)1 (once daily). Polatuzumab vedotin (1.8 mg/kg) was given on C1D2 and D1 of C2-6 (21-day cycles; once daily). Glofitamab was given as step-up doses in C1 (D8, 2.5 mg; D15, 10 mg) followed by 30 mg on D1 of C2-12 (21-day cycles; once daily). Polatuzumab vedotin was given for six fixed-duration cycles, and glofitamab for 12.
> 
> RESULTS: As of September 2, 2024, 129 patients with LBCL (HGBCL; n = 44, 34.1%), received ≥1 dose of study treatment. The median age was 67 years (range, 23-84), and 63.6% were male. Patients had received a median of 2 (range, 1-7) previous lines of treatment (previous CAR T-cell therapy, n = 28, 21.7%). The independent review committee-assessed overall response rate was 78.3% (complete response rate, 59.7%). The median progression-free survival and overall survival (OS) were 12.3 and 33.8 months, respectively (median OS follow-up time, 32.7 months). The most common adverse event (AE) was cytokine release syndrome (43.4%; grade 1-2: 41.9%; one grade 5 event). Grade 3-4 AEs occurred in 58.9% of patients; 9.3% had grade 5 AEs, and 14.7% discontinued treatment because of AEs.
> 
> CONCLUSION: Glofit-Pola demonstrated high efficacy and durable responses, with manageable safety, in heavily pretreated patients with R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy failure.

> **中文摘要：**
> 目的：对于复发/难治性（R/R）大B细胞淋巴瘤（LBCL），尤其是高级别B细胞淋巴瘤（HGBCL），仍存在对更有效治疗方案的未满足需求。本研究呈现了一项Ib/II期研究（ClinicalTrials.gov标识符：NCT03533283）的主要分析，评估Glofitamab联合Polatuzumab Vedotin（Glofit-Pola）在R/R LBCL患者（包括HGBCL及既往接受过嵌合抗原受体（CAR）T细胞治疗者）中的疗效与安全性。
> 
> 方法：患者在第1周期（C1）第1天（D1）接受1000 mg Obinutuzumab（每日一次）。Polatuzumab Vedotin（1.8 mg/kg）在C1D2及C2–C6的D1给药（周期为21天；每日一次）。Glofitamab在C1中采用递增剂量方案给药（D8：2.5 mg；D15：10 mg），随后在C2–C12的D1给予30 mg（21天为一周期；每日一次）。Polatuzumab Vedotin固定治疗6个周期，Glofitamab治疗12个周期。
> 
> 结果：截至2024年9月2日，129例LBCL患者（其中HGBCL，n=44，占34.1%）至少接受过1次研究药物治疗。患者中位年龄为67岁（范围23–84岁），男性占63.6%。患者既往接受的治疗线数中位为2线（范围1–7线），其中既往接受CAR T细胞治疗者28例（21.7%）。独立评审委员会评估的总缓解率为78.3%（完全缓解率59.7%）。中位无进展生存期为12.3个月，中位总生存期（OS）为33.8个月（中位OS随访时间32.7个月）。最常见的不良事件（AE）为细胞因子释放综合征（43.4%；1–2级占41.9%；1例5级事件）。3–4级不良事件发生率为58.9%，9.3%的患者出现5级不良事件，14.7%的患者因不良事件停药。
> 
> 结论：Glofit-Pola在经多线治疗的R/R LBCL患者（包括HGBCL及既往CAR T细胞治疗失败者）中表现出较高的疗效与持久缓解，并具有可管理的安全性。

### 第二部分 AI 大师评价

该研究是一项Ib/II期临床试验，旨在评估Glofitamab联合Polatuzumab Vedotin在复发/难治性大B细胞淋巴瘤患者中的应用价值。结果显示该联合方案在既往多线治疗失败、甚至CAR T治疗后复发的患者中仍具较高的客观缓解率和较长的生存期。主要毒性事件可预测且多为可控级别。创新点在于双靶向抗体联合药物的协同策略，为高危LBCL患者提供了新的治疗选择；但需进一步随机对照研究以验证长期获益与安全性。

---

速递结束，祝您工作愉快！